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Cisplatin (cis-diarnrninodichloroplatinum[II]) is a widely used 
antineoplastic agent, which is believed to work by means of covalent 
interaction with DNA. Complexes of this compound were made with the 
B-DNA dodecamer C-G-C-G-A-A-T-T-C-G-G-G by diffusion of the drug into 
pregrown DNA crystals, and a structure determined to 2.6 Angstrom 
resolution by molecular replacement. Cisplatin was found to bind with 
partial occupancy at three discrete sites: G16 (61%), C4 (~%) and 
GlO ( 22%), in each case by means of a single covalent bond from the 
metal to guanine N7 in the major groove. The square plane of the 
metal complex ligands is rotated out of the plane of the guanine base, 
with one of the ligands that is cis to the guanine N7, presumably an 
amine, in a position to make a hydrogen bond with guanine 06; the 
long metal-06 distance precludes the possiblilty of a direct metal-06 
bond. The DNA structure itself is essentially undisturbed by the 
metal binding; the ooly change is a slight notion of the bound 
guanines outward into the major groove toward the metals, resulting in 
a slight opening up of the groove but without pulling the b3.se-pairs 
out of the helix stack. The structure shows that it is not possible 
for a direct N7-to-N7 crosslink between two adjacent bases by the 
metal to exist in an intact B-DNA double-helix. It is suggested that 
the observed structure is a prim3.ry nx:>de of binding of the drug, which 
then could become this postulated active form upon disruption of the 
DNA duplex. 
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II. Lac headpiece-operator complex 
The lac repressor protein of E. coli controls expression of the 
genes necessary for lactose utilization by the organism. It is a 
tetramer of four identical subunits of 355 amino acids each, each of 
which is divided into a 51 amino acid N-terminal DNA-binding, or 
"headpiece" domain and a 300 residue C-terminal regulatory region, or 
"core." In the presence of lM Tris.HCl pH 7 .5 and 30% glycerol, the 
headpiece can be isolated intact by proteolytic digestion and is 
believed to retain its specific DNA binding properties for the lac 
operator site. A large-scale purification scheme for the headpiece 
protein has been developed, using a specific protease-affinity colurrm 
to eliminate all residual proteolytic activity from the prep, thus 
making it possible to isolate large quantities of the 
protease-sensitive fragment in stable form for crystallization trials. 
Attempts to crystallize the protein by itself resulted only in fibrous 
microcrystals. But cocrystallization trials with a 21 base-pair lac 
operator DNA oligomer yielded what appear to be small cocrystals, too 
small to characterize, under conditions in which neither the protein 
nor the DNA by themselves would crystallize. 
III. Hoechst 33258-Complex with DNA 12mer 
Hoechst 33258 is a widely used histological stain that f orrns a 
fluorescent complex with DNA, showing strong preference for AT-rich 
regions. Crystals were grown of a 1: 1 complex of the dye with the 
B-DNA 12rner C-G-C-G-A-A-T-T-C-G-C-G, and a structure was determined to 
2.2 Angstrom resolution. The compound was found to bind noncovalently 
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in the minor groove, with its aromatic phenol and two benzimidazole 
rings spanning three bases of the A-A-T-T region, and its aliphatic 
piperazine ring binding in the adjacent C-G-C-G region. Three 
hydrogen bond contacts were found to bridge between adjacent 
base-pairs, the bridging resembling that by water rrolecules in the 
native structure. This bridging of base pairs was achieved via three 
amine groups on the dye. These all undoubtedly help to stabilize the 
interaction, but the shape of the compound allows a good hydrogen 
bonding interaction of normal length through only one of these 
contacts. The piperazine ring, because of its orientation 
perpendicular to the other rings, is unable to bind into the narrower 
minor groove of the Kr region and must bind in the wider CG minor 
groove. In a second conformation of the dye, also seen in the 
structure, the piperazine ring points out of the minor groove because 
of a rotation of the benzimidazole ring to which it is attached around 
its bond to the other benzimidazole. In this orientation, the 
piperazine ring no longer makes contact with the DNA, and therefore 
the drug is not restricted to binding at a site containing GC 
base-pairs. As a result, it could bind within a region of contiguous 
Kr base-pairs without the problem of steric clash due to the 
piperazine ring. 
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Introduction 
X-ray crystallography must rank as the only science in which the 
limiting factor is the availability of suitable subject matter. To 
study a subject by crystallographic techniques, one must be able first 
to crystallize it; frequently, such a study ends here, as only a few 
of the many things that one would like to be able to study in this way 
are amenable to crystallization. As a result, crystallographers study 
what they can crystallize, for it is only in a few fortunate cases 
that one is able to crystallize what one would like to study. 
For many years, this was the case in the study of nucleic acids 
by crystallographic techniques. The early work in this area was done 
entirely by diffraction analysis of drawn natural fibers, because none 
of the species of nucleic acids that it is possible to isolate from 
natural sources, except for a few of the transfer RNA IIX)lecules, can 
be crystallized. From this work, it was at least possible to get 
cylindrically averaged data on long stretches of these nnlecules at 
the molecular level, and based on this information, the now classical 
A and B forms of DNA were first recognized (2, 5). Nevertheless, the 
fruitfulness of this work can be measured by the fact that the 
structural basis of DNA as a self-complementary double helix was first 
deduced by Watson and Crick (8) largely from these data • This 
brilliant insight fused the then disparate fields of biochemistry and 
genetics into the grand synthesis of molecular biology and changed our 
understanding of the l:asis of life forever. 
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In recent years, this state of affairs for nucleic acid 
crystallography has all changed. Thanks largely to the work of 
Khorana and coworkers (3), it has become possible to make defined 
sequences of nucleic acids synthetically, in quantities large enough 
and of sufficient purity to make growth of single crystals of many of 
these sequences a reality. As a result, these molecules have now come 
under the scrutiny of high resolution crystallographic analysis, and 
the structures of many of these compounds have been determined at the 
atomic level. As proof of the great potential for new insights into 
nucleic acid structure that this has heralded, the first such 
structure of a DNA sequence, that of the hexamer C-G-C-G-C-G by Rich 
and coworkers (7), astounded the world by revealing the existence of a 
previously unsuspected conformation of DNA, the left-handed Z form, 
the implications of which are still being debated with respect to the 
process of gene regulation in the living cell. Since then, single 
crystal structures of the classical A and B forms of the early fiber 
studies have been also been determined (1, 9), and much has been 
learned from these studies about the architecture of DNA at the atomic 
level. 
What these structures provide us with are snapshots of specific 
instances of DNA molecules, as frozen out in the crystalline state. 
Such pictures define what the molecule does in each of these 
instances, showing explicitly how a particular set of conditions 
affect the sequence, and how the sequence can respond to these 
conditions. When studied as a series of sequences, they show how 
sequence and structure interact, providing a basis for understanding 
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how a seemingly uniform rrolecule can in fact be rich in structural 
detail, which makes different sequences become different structures. 
And, finally, when studied in complex with other rrolecules which 
interact with it, they can define the nature of these interactions, 
and how structure affects function. 
This work describes the results of three such studies of nucleic 
acids and what these studies have told us. The first of these is of a 
complex of the antiturror drug cisplatin with the B-DNA 12mer 
C-G-C-G-A-A-T-T-C-G-~ and might be thought of as "taking advantage 
of a good thing." The complex was originally used as a phasing 
derivative in the solution of the native structure by nultiple 
isorrorphous replacement techniques (9). Since the compound is such an 
important antitumor agent, a study of this complex as an independent 
structure was undertaken in order to see how the drug interacted with 
DNA; in particular, the hope was to see what makes cisplatin such an 
effective antiturror drug, while its trans isomer is therapeutically 
inert. The results were at first rather disappointing in that they 
showed virtually no effect on the DNA from binding of the drug. But 
nonetheless, the details of the structure did place constraints on 
what sort of complexes the drug would be able to form with DNA in the 
double-helical state, and because of this we termed this complex the 
"primary rrode of binding" of the drug to DNA in the native form (10). 
The second study involved a continuation of an earlier project on 
a complex of the lac repressor protein and its DNA binding site and 
would definitely have to be thought of as "shooting the moon." The lac 
operon is the rrost widely studied DNA regulatory system, and a 
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structure of this repressor and operator in complex would tie together 
the enormous body of biochemical and genetic information which is 
known about it into a precise mechanism for gene regulation in living 
systems. Begun in this group by John Rosenberg even before DNA 
synthesis had become practical for crystallographic use, the original 
goal was to cocrystallize the entire lac repressor molecule with a DNA 
restriction fragment containing its consensus operator binding site. 
Unfortunately, the original project had to be abandoned after several 
years of effort failed to produce suitable crystals of the complex. 
It was revived, however, because of two subsequent developments: 
first, the ability to isolate a small proteolytic fragment of the 
large, unstable repressor called the lac headpiece, as a small, stable 
protein which still possesses the specific DNA binding activity of the 
whole repressor; and second, the advent of the new DNA synthesis 
techniques, which made it possible to synthesize the 21 base pair 
operator site as a pure, synthetic DNA oligomer. Unfortunately, 
however, this second attempt was also unsuccessful, and also for the 
same reason as before, But this time the project shows some promise 
for success with additional effort. 
The final work consisted of the study of a complex of the B 12mer 
with the DNA fluorochrome and anthelmintic Hoechst 33258. Hoechst is 
a member of a class of DNA binding molecules, many of which show 
promise as antitumor drugs, which bind to DNA by means of noncovalent, 
nonintercalative interaction with the minor groove. In addition, 
Hoechst is structurally similar in several key respects to the 
antitumor antibiotic netropsin, the structure of whose complex with 
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the same 12rner had previously been determined in our lab ( 4). For 
this reason, a structural study of the complex of Hoechst bound to the 
DNA oligorner also was tried, in the hope that this would be "going for 
a sure thing." Fortunately in this instance, it was. The structure of 
the complex gave a wealth of inf orrnation on how this molecule acts as 
a minor groove binder, confirming many of the details that were 
deduced f rorn the netropsin complex of how these molecules bind to DNA, 
and providing additional insights into how its unique structure 
influences its ability to bind to DNA (6). 
-7-
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Introduction 
The story of the antiturror compound cisplatin is a typical 
example of serendipity in scientific research. Discovered by accident 
during a study of the effects of electric fields on bacterial growth 
(7), in which strange distortions of normal binary fission were found 
to be caused by hydrolysis products of the supposedly "inert" platinum 
electrodes being used, it has proven to be one of the most effective 
antineoplastic agents known, curing several forms of testicular and 
ovarian cancer, and in conjunction with other agents providing 
effective treatment of a wide range of cancers (4). From very early 
on, the activity of cisplatin was thought to result from interaction 
with DNA. Current opinion favors the idea that the drug's active 
lesion is an intrastrand crosslink between the N7 atoms of two 
adjacent guanine bases in DNA, interfering with DNA replication and 
transcription ( 5). Several structures of the compound complexed with 
nucleosides and nucleotides have shown the details of such an 
interaction (1, 2, 3), and recently a structure of cisplatin complexed 
with a pGpG diner has demonstrated that this complex can occur in an 
intact strand of DNA (8). Nevertheless, the reason why such a lesion 
should make cisplatin so effective an antineoplastic agent in vivo has 
remained obscure. Efforts to capitalize on this insight to produce 
more effective forms of the drug have not yet produced agents that are 
any more effective than the parent compound. 
Our involvement with cisplatin also began in a rather roundabout 
way, when, during the structural solution of the B-DNA dodecamer 
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C-G-C-G-A-A-T-T-C-G-C-G, cisplatin was used to produce a heavy atom 
derivative for multiple isomorphous phase analysis of the native 
structure (9). Because of the importance of the compound as an 
antineoplastic agent, we decided to solve the complex of the drug with 
the B-form 12mer as an independent structure, so that we could study 
at first hand the details of its interaction with a segment of 
double-helical DNA. This was done by diffusing the drug into 
pre-grown crystals of the dodecamer, collecting diffraction data on 
the crystals and solving the structure by molecular replacerrent. In 
this way, we would see how the drug interacts with DNA in the crystal, 
in which the helices are effectively locked into the double-helical B 
conformation. 
What we found largely confirmed the results of the other 
crystallographic and solution studies, as well as added a few new 
insights into limits on its possible interaction with DNA in the 
double-helical form. As expected from previous work, the compound 
bound to the DNA in our crystals solely to N7 atoms of three guanine 
bases in the duplex. As predicted by the work of Gocxlgame et al. 
( 3), one corner of the square planar complex around Pt was occupied by 
the guanine N7 atom and another by a water molecule bridging between 
Pt and the guanine 06. (Waters presumably replace chlorines in the 
aquated form of the complex.) Such a Pt-06 bridge requires tilting the 
metal coordination plane sore 60 degrees out of the plane of guanine. 
Sequence effects also were seen on occupancy of the rretal at different 
sites, with differences not only between guanines adjacent to 
different tases in the sequence but also between two guanine sites on 
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syrrnnetrically related bases on the palindromic oligomer, suggesting 
that local conformational effects of the helix played a role in 
determining binding as well. Finally, in agreement with results from 
solution studies, we found that at the low levels of binding seen in 
this structure, binding of the metal produced no major distortions of 
the helix at all, with a slight motion of the bound base-pairs toward 
the major groove being the only visible effect of the drug on the DNA. 
We interpreted our results as representing the probable primary mode 
of binding of cisplatin with B-DNA in the cell, with this monodentate 
binding setting the stage for the formation of later bidentate binding 
on some occasion in which the helix would be disrupted, as in 
replication or repair. A full report of the cisplatin structure 
analysis is given in the following paper. 
-12-
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The primary mode of binding of cisplatin to a 8-DNA dodecamer: 
C-G-C-G-A-A-T-T-C-G-C-G 
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Communicated by J .H. Miller 
When cisplatin [cis-diamminodichloroplatinum(IOJ is diffus-
ed into pre-grown crystals of the 8-DNA double-helical 
dodecamer C-G-C-G-A-A-T-T-C-G-C-G, It binds preferen-
tially to the N7 positions of guanines, with what probably is 
an aquo bridge between Pt and the adjacent 06 atom of the 
same guanine. The entire guanine ring moves slightly toward 
the platinum site, into the major groove. Only three of the 
eight potential cisplatin binding sites on guanines actually are 
occupied, and this differential reactivity can be explained in 
terms of the relative freedom of motion of guanines toward 
the major groove. This shift of guanines upon ligation may 
weaken the glycosyl bond and assist in the depurination that 
leads to mismatch SOS repair and G.C to T.A transversion. 
Key words: cisplatin/B-DNA/X-ray structure 
Introduction 
Cisplatin [cis-diarnminodichloroplatinum(II)] is one of the 
most effective and extensively studied inorganic antitumor 
drugs . In contrast, for reasons that are not fully understood, 
its transplatin isomer (trans-Pt(NHJ)zClz) exhibits little anti-
neoplastic activity (Rosenberg et al., 1969; Prestayako et al., 
1980). Cisplatin is believed to interfere with DNA replication 
and transcription in a manner similar to that of alkylating 
agents (Harder and Rosenberg, 1970; Howle and Gale, 1970; 
Taylor et al., 1976). In solution under normal physiological 
conditions, cisplatin binds most strongly to the N7 position of 
guanine, with lesser attraction for adenine and cytosine and 
none for thymine or uridine (Mansy et al., 1973, 1978). 
Single crystal X-ray structure analyses have been carried 
out previously for complexes of cisplatin or of cis Pt(en)Cl2 
(en = ethylenediamine) with inosine monophosphate or with 
· guanosine (Goodgame et al., 1975; Gellert and Bau, 1975; 
Cramer et al., 1980). In each case the platinum atom bridges 
the N7 positions of two guanine rings, with cis ligation to Pt. 
This has led to the suggestion that cisplatin might act in vivo 
by making interstrand or intrastrand cross-links between 
guanines. lnterstrand cross-linking (Horacek and Drobnik, 
1971; Roberts and Pascoe, 1972; Zwelling et al., 1979) would 
necessitate unwinding of the double helix, since a cisplatin 
group bound to guanine in the bottom of the major groove 
would be inaccessible to another strand from the same or a 
different helix, for the second bond. Intrastrand cross-linking 
could be achieved between adjacent guanines along a poly-
nucleotide chain (Cohen et al., 1980; Lippard, 1982), but only 
© IRL Pr= Limited, Oxford, England. 
at the price of destacking the bases and tipping the N7 posi-
tions toward the metal site in the major groove. 
Alkylating agents such as benzo[a]pyrene, 2-acetylamino-
fluorene and aflatoxin Bl have another important effect on 
DNA, in addition to simple alkylation and cross-linking. 
They are potent mutagens, introducing G.C to T.A transver-
sions in a parallel fashion (Foster et al., 1983). The common 
feature of these alkylation adducts seems to be a weakening 
of the glycosyl bond leading to depurination, followed by in-
sertion of adenine opposite the depurinated site by the SOS 
repair system of the cell (Witkin, 1976, 1982). Miller (1983) 
has suggested that cisplatin might also mimic this property of 
alkylating agents, leading to mutagenesis with transversion as 
well as cross-linking. In support of this idea, Brouwer et al. 
(1981) have found that cisplatin strongly favors G .C to T.A 
transversions among 650 nonsense mutations produced in the 
lac! gene of Escherichia coli, supporting the idea that what is 
occurring is depurination followed by bypass repair. 
Pt(dien)Cl - appears to strengthen the glycosyl bond when it 
complexes with the N7 position of guanine (Johnson, 1982; 
Johnson et al., 1982). However, as these authors themselves 
point out, 'The enhanced biological activities of cis-PDD 
compared with trans-PDD and [Pt(dien)Cl]Cl are a conse-
quence of different platinum-DNA adducts formed by these 
compounds in vivo'. For example, cisplatin is a potent 
mutagen, with excision repair and daughter strand gap repair, 
and has clinically useful antitumor activity; Pt(dien)Cl - , in 
contrast, is only a very weak mutagen, shows no evidence of 
repair, and has no antitumor activity. These observations 
provide strong circumstantial support for the idea that 
mutagen activity involves as an early step the weakening and 
rupture of the glycosyl bond, and subsequent depurination. 
Regardless of whether the ultimate outcome is cross-linking 
or mutagenesis, the initial biological interaction of cisplatin 
with double-helical DNA almost certainly is binding to 
guanine N7 with loss of one of the chloro (or rather, aquo) 
ligands. As Lippard (1982) has pointed out, aqueous solution 
of cisplatin is followed by displacement of chlorides by water 
molecules. Displacement of one water and ligation to N7 then 
follows, but it is unclear whether a second interaction occurs 
with the adjacent 06 under physiologically reasonable condi-
tions (Chu et al., 1978). The distance between Pt and 06 is 
too long for a direct Pt-0 bond, but too short to accom-
modate an intermediate bridging water molecule unless the 
square planar Pt complex is rotated about the Pt-N7 bond, 
and out of the plane of the guanine rings (Goodgame, 1975). 
In lieu of co-crystallized complexes of cisplatin with G-G-
containing DNA oligomers, thus far unattainable, we have 
solved the crystal structure of the diffusion complex of 
cisplatin with the B-DNA double-helical dodecamer of se-
quence C-G-C-G-A-A-T-T-C-G-C-G. Attempts to achieve 
complete substitution or 100% binding to the major site led 
to destruction of crystal order as reflected in degradation of 
the X-ray pattern, an observation that may support the 
hypothesis that cisplatin binding ultimately deforms and 
1201 
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Table I. Binding of cisplatin to C-G-C-G-A-A-T-T-C-G-C-G as a function of con~ntration 
Data SCI Native 
Cell dimensions (A) a 24.87 
b 40.39 
66.20 
Resolution. d (A) 1.9 
Residual error, R. All data : 23.90/o 
Two-sigma data : 17.811/o 
P~nt site occupancy Gl6 
G4 
GIO 
Pt-N7 bond length, Gl6 <A > 
Apparent guanine shift (A) 




























Fig. I. Unrolled ladder diagram of the major groove of the B-DNA 
C-G-C-G-A-A-T-T-C-G-C-G dodccamer, showing the eight potential 
cisplatin binding N7 sites as circles. Numbers 1 - 3 indicate observed bin-
ding sites in order of decreasing occupancy by cisplatin complexes. No bin-
ding was observed at the five positions marked by circled X. 
destroys the double helix. However, lower levels of substitu-
tion yield a clear indication of the cisplatin binding sites, and 
a pattern of selective binding to guanines that provides infor-
mation about the primary binding steps in the interaction of 
cisplatin with double-helical DNA. The most highly substitu-
ted data set has been refined to completion, and two other 
sets have been refined to the point where meaningful struc-
ture comparisons can be made with the primary set. 
Results 
The three data sets, labeled Pt!, Pt2 and Pt3 in order of in-
creasing cisplatin substitution, are listed in Table I. In set Pt2 
1202 
Ptl Pt2 Pt 3 
24.36 24.33 24 . 16 
40.05 -40.08 39.93 
66.13 66.26 66.12 
2.5 2.2 2.6 
20.00/o 27.0% 16.60/o 
11.20:-, 
200/o 38 0'i'o 61 "'• 
JO% 1711/o 301t.'(I 
13 % 220/o 
2.51 2.43 2.16 
0.51 0 .43 0. 16 
2.0 2.24 2.03 
2.92 2.77 
the emphasis was on resolution of the data; in Pt3, on max-
imal substitution. The Pt3 set was chosen for complete refine-
ment (see Materials and methods), to a final zero-sigma 
residual error or R factor of 16.60/o, and a two-sigma R factor 
of only 11.20/o , the lowest values obtained in any of our oligo-
nucleotide refinements. The double-helical B-DNA 
dodecamer C-G-C-G-A-A-T-T-C-G-C-G has eight guanines 
that could serve as binding sites for cisplatin, as indicated by 
circles on the rungs of the DNA ladder in Figure I . No more 
than three of these were occupied by cisplatin even in the 
most highly substituted crystal, and always in the order of 
decreasing affinity: Gl6, G4, GIO. As Table I indicates, in 
the most highly substituted Pt3 set, site Gl6 exhibits 61 O/o oc-
cupancy, with 300/o at G4 and 220/o at GIO. Such incomplete 
site occupancy is not without precedent in other crystal struc-
ture analyses of complexes of cisplatin with organic bases. 
Goodgame (1975) reacted cisplatin with inosine monophos-
phate prior to crystallization, but still obtained a non-
stoichiometric compound with only 0.56 platinum atoms per 
two inosine bases. The relative site occupancies in the 
cisplatin complex of C-G-C-G-A-A-T-T-C-G-C-G listed in 
Table I can be given a straightforward structural explanation, 
as described below. 
Figure 2 shows a minor groove stereo pair drawing of the 
refined Pt3 structure, with cisplatin groups depicted at sites 
G4, Gl6 and GIO from top to bottom. The three ligands 
drawn around each platinum atom were located from dif-
ference electron density maps and then refined as described in 
Materials and methods. No restraints were applied to tie the 
ligands to the platinums during refinement, and the fact that 
the PtL3 complexes remained intact, with reasonable Pt-L 
bond lengths of -2.0 A as listed in Table II , indicates that 
even at less than complete substitution, real inforrnation 
about the structures of the complexes is being obtained . 
Platinum positions may be regarded as secure; ligand posi-
tions are reasonable and suggestive. 
A close up view of sites Gl6 and GIO in the bottom half of 
the helix is provided by the stereo drawings of Figure 3. Bear-
ing in mind the provisional nature of the ligand sites, it ap-
pears that the platinum atom is indeed bridged by a ligand, 
probably water, to the adjacent 06 atom on the same guanine 
ring, and that the square plane of Pt ligands is rotated out of 
-15-
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Fig. 2. Major groove view of the cisplatin complex of C-G-C-G-A-A-T-T-C-G-C-G as refined from data sel Pt3. Base pair Cl.G2A is a1lhe1op, and 
GJ2.CJ3 is al lhe bonom . Pl atoms at guanines G4 , Gl6 and GIO (from top to bo11om) are represented by their anisotropic thermal ellipsoids. The three 
smaller crossed spheres around each Pt are ligand sites ob1ained as described in Materials and methods. Other aloms are P, 0, N and C in order of descen · 
ding size. 
Table II . Cisplatin-DNA complex geometry 
GI6 G4 GIO 
Percent occupancy 610/o 300io 220/o 
Bond lengths (A) 
P1-N7 2.16 2.31 2.23 
Pl-LI 2.02 1.75 1.83 
Pt-L2 1.81 2.25 2.10 
Pt-U 2.00 2.23 2.13 
Bond angles (0 ) 
LI-P1-L2 166 175 173 
Ll-P1-L3 98 95 105 
L2-P1-L3 79 85 82 
the guanine plane as in Figure 4. So far this only confirms ex-
pectations from previous crystal structure analyses with bases 
and nucleotides. However, Figure 3 also indicates that base 
pairs in the cisplatin complex are shifted relative to their posi-
tions in the native structure. At the most highly substituted 
Gl6 site, the guanine ring moves towards the platinum, bring-
ing the hydrogen-bonded cytosine with it. Cytosine Gl5 just 
below it in Figure 3a moves in the same direction, but adenine 
A I 7 just above it moves in a different direction along the long 
axis of the base pair, indicating that what is being observed is 
not a rigid-body shift of the entire helix, but a local deforma-
tion . At the less highly substituted GIO site (top rear of Figure 
3a), the guanine appears to pivot so the five-membered ring 
again moves toward its bound Pt site. 
Discussion 
An X-ray crystal structure analysis gives the averaged 
molecular structure over the entire crystal. If substitution 
were complete, one would observe an image of the pure cis-
platin/ DNA complex. If there were no substitution, one 
would see the image of the parent DNA molecule. For partial 
substitution, what is observed is a composite image of both 
structures, with the cisplatin-bound image at each site 
weighted according to the degree of substitution at that site. 
If the binding of cisplatin involves a displacement of the 
guanine ring, then for partial occupancy sites the apparent 
position of the ring will be intermediate between that of the 
parent helix and that of the l : I cisplatin complex. This seems 
the best explanation of a curious observation that arises when 
the three structures with different levels of cisplatin substitu-
tion are compared : Pt l, Pt2, and Pt3 (Table I). The apparent 
Pt-N7 bond length of 2.5 l A in the low-substitution Pt I 
structure is far too long, but the bond becomes shorter in Pt2 
and Pt3 as the degree of substitution increases. Linear ex-
trapolation of a plot of bond length versus percent substitu-
tion leads to a Pt-N7 distance of I .8 A at 100% substitution, 
overshooting slightly the expected l.97-2.02 A (Goodgame 
et al., 1975; Gellert and Bau, 1975; Cramer et al., 1980), bu1 
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R.M. Wing er al. 
Fig . 3. Plan view (a) and major groove edge view (b) of cisplatin sites Gl6 and GIO and their immediate surroundings. Base pair T8 .Al7 is nearest the viewer 
in (a) and a1 the top in (b) . Base pair GIO.Cl5 is farthes1 from the viewer in (a) and a1 the bouom in (b) . Platinum and ligand atoms are displayed as in 
Figure 2. and other crossed spheres are P.O. N and C in order of d=nding size. The small. uncrossed sphere beside each atom of the DNA helix indica1e> 
the location of the equivalent atom in the native dodecamer structure withou1 cisplatin. (a) Shows particularly clearly tha1 binding of cisplatin IO 1he N7 of 
guanine Gl6. the moSI highly substituted site, pulls the en1ire base pair inlO the major groove in the direction of the Pt atom. A similar bu1 smaller effec1 is 
















Ftg. 4. Ligation geometry suggested by the Pt3 structure analysis. The N7 
of guanine supplies one of the four square planar Pt ligands. A second 
ligand L2. most probably a water molecule, bridges the Pt and the guanine 
06. Ligands LI and L3 probably are the ammonia molecules of the 
original cisplatin complex. Since the Pt atom is symmetrically located 
relative to the geometry of the five-membered ring of guanine, the separa-
tion between Pl and 06 is too shon to permit a bridging ligand unless the 
square planar Pt complex is rotated out of the plane of the guanine. This 
same geometry was sugges1ed by Goodgame et al. (1975) as the initial 
mode of binding of cisplatin to double-stranded DNA. 
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indicating a substitution-dependent effect on apparent bond 
length. 
This observation and the atom shift evidence in Figure 3 
both indicate that when cisplatin binds, the guanine ring 
moves out of the base pair stack of the double helix into the 
major groove. Since the apparent shift in the composition im-
age is 0.5 A for 6107o occupancy, one might expect a full-
occupancy real shift of nearly an Angstrom. This could be 
enough to destabilize the helix, disrupt the crystal, and 
perhaps even to weaken and break the glycosyl bond that at-
taches the guanine ring to the deoxyribose. Hence the present 
structure analysis, even though it is concerned directly only 
with the initial steps of cisplatin-DNA interaction , also pro-
vides support for the idea that depurination and mutagenesis 
are involved in the overall process. 
The radically different degrees of substitution at the eight 
guanine sites along the double helix at first are surprising. but 
they have a simple explanation in terms of local guanine en-
vironment . The occupancy trends in Table 1 can be factored 
into two components: (i) increased reactivity of guanines the 
farther they are from the ends of the helix, and (ii) greater 
reactivity in the bottom half of the molecule than the top. The 
occupancy ratio between equivalent sites four base pairs in 
from each end, Gl6/ G4, is 2.0-2.2 in all three data sets of 
Table I, and that between the sites four and three base pairs in 
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from the same end, GJ6/G IO, is 2.8-2.9. An occupancy 
ratio of 2.3 corresponds at 298 K to a free energy difference 
of 0.5 kcal / mo!. Why should symmetrically equivalent posi-
tions on the two helix strands exhibit a difference in binding 
energy of a little less than 0.5 kcal, and why should the bind-
ing energy at the fourth base pair from the end differ from 
that at the third base pair by a slightly greater amount? 
The increased reactivity of guanines the farther they are 
from the ends of the helix, probably is explained by inter-
molecular interactions in the crystal. As can be seen from 
Figure 3 of Wing et al. ( 1980), the crystals contain columns of 
helices with overlapping ends. The minor grooves of two suc-
cessive helices are interlocked, with the first two base pairs of 
one helix hydrogen-bonded to the first two base pairs of the 
next helix via N3 . .. H-N2 and N2-H ... N3 bonds between 
guanines. Hence the first two base pairs in from each end of 
the helix are immobilized on the minor groove side, and can-
not shift toward the major groove to accommodate cisplatin 
binding. The third base pair is somewhat less constrained, 
and the fourth pair is freest of all. The reactivity of a par-
ticular guanine appears to be related directly to its freedom 
from constraints, and its ability to move toward the potential 
cisplatin site. 
Why should the extent of cisplatin binding, at the same 
distance in from the end of the helix, differ between the two 
ends? The molecules after crystallization have an overall 19° 
bend in helix axis, and the sharpest bending occurs at the up-
per end of the molecule in Figure 2, where a spermine 
molecule bridges the major groove in the parent DNA struc-
ture. The molecule appears to close down its major groove 
slightly around the spermine. In the cisplatin complex the 
spermine molecule is displaced by the diffused-in cisplatin, 
but the asymmetric bending at the two ends of the molecule 
remains. In effect, the top four base pairs are inclined to the 
left in Figure 2 by rolling the fourth base pair against its 
neighbors along its long axis (Dickerson et al., 1983). This 
constricts the major groove, and probably makes it difficult 
for guanines G22 and G4 to slip toward the major groove, 
hence decreasing their affinity for cisplatin. 
In summary, the initial steps of binding of cisplatin to this 
B-DNA double helix involve ligation to the N7 position of 
those guanines that are most free to move slightly into the 
major groove. A second, stabilizing interaction appears to 
form between the platinum and the adjacent 06 atom on the 
same guanine, most probably involving a water molecule as a 
bridge. This may be the basis for the difference in reactivity 
of the cis and trans isomers. The destruction of crystal order 
that always accompanies high substitution makes it clear that 
this is not the entire story; the binding that we see here is only 
the preface to a more serious rearrangement. This may in-
volve distortion of the helix during formation of Pt cross-
links between pairs of guanines. The shift of guanine posi-
tions upon interaction with Pt suggests that it may also in-
volve straining the glycosy bond and depurination, whch 
could lead to mutagenesis during the repair process. What is 
needed at present is a structure analysis of a cisplatin complex 
containing the G-G sequence, in which the complex is formed 
in solution, purified , and crystallized . Efforts in this direction 
are continuing. 
Materials and methods 
Native C-G-C-G-A-A-T-T-C-G-C-G crystals grown by vapor diffusion as 
described previously (Wing el al. , 1980; Dr"" el al., 1981) were equilibrated 
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with solid cisplatin or with 25- 550/o saturated solutions of cisplatin in 40:60 
water/M PD (2-methyl·2.4-pen1anediol) al 4°C for periods of a few days to 
several weeks. The derivatized crystals !hen were back-soaked in fresh 
platinum-free MPD/ water solution for 4-24 h to remove any non-CO\'alentl~ 
bound or imerstitial platinum. Attempts to obtain high occupanc~ of 
platinum binding sites, e.g., a Pt to DNA si1e ratio close to I: I, invariably led 
to destruction of the X-ray pattern from the outside inward, and to incr~ 
sensitivi1y of the crystals to X-ray damage. AJthough backsoaking wa~ found 
10 aid the situation, all cisplatin-substiruted crystals remained very sensitive 10 
X-ray irradiation; the useful data collection lifetime fell from - 200 h for the 
na1i ve dodecamer to 25 h for the highest level of Pt subSlitution . 
Three data sets were collocted at d ifferent level~ of substi1u1ion, as li sted in 
Table I. Pt I. the leas! substituted but moSl ideally isomorphous se1. was used 
for phase analysis of the parent or native structure. The higher substitu1ed of 
the remaining sets, Pt3, was selected for complete Jack-Le\·itt restrained 
energy refinement as described by Fratini et al. (1982). leading to a final 
residual error or crystallographic R factor of 16.60/o for all daia or 11.2% for 
1hose reflections above the two-sigma confidence level. 128 solvent peak s were 
added gradually during refinement , using the strategy described by Dre" and 
Dickerson (1981) and by Kopka et al. (1983) . 
Initial ligand positions around the Pt sites were obtained from difference 
maps in which the DNA, ordered solvent, and P1 atoms were subiracted out. 
These ligands, roughly in a square planar array around each Pt si te . then were 
refined in the Jack-Levitt procedure Y.ithout restraints. i.e .. independently of 
any specified connecti?n to the P1 atoms. The fact !hat the Pt-ligand position> 
remained around 2.0 A (Table II) is evidence tha1 the si ies are real and tha1 the 
refinement is meaningful. Al the very end of 61 cycles of Jack-le,;n refine-
ment. one more test of ligand geometry was made: the DNA atoms were held 
fixed, ligand atoms were eliminated, and Pt atoms were subjec1ed to full-
matrix. anisotropic least squares refinement. New ligand positions then were 
obtained from difference maps, and refined isotropically along with the 
anisotropic Pt. This refinement was well·behaved for the Gi6 cisplaiin com· 
ple.x with 61 O/o occupancy, but ligand positions wandered away from 1he P1 
positions for the two less-substituted sites. The final coordinate set, which has 
been deposited " i th the Brookhaven Protein Data Bank for general distribu-
tion. is a composite set: anistropic data for the three Pt awms along with their 
isotropic equi'"alents, full-mairix refined positions for the ligands of site G 16. 
and bes1 Jack·Levin refined posi1ions for the ligands of G4andG10. and for 
the DNA . The original X-ray diffraction data also have been deposi1ed. 
The Pl.2 data set with intermediate substitution was refined onl\" to the 
point where no funher motion of atoms in the D!\A was occurring. a~d it was 
judged that no funher comparative strudure information would resuli b~ 
continuing. The main value of this was its P1-N apparent bond distance. 
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Nole added in proof 
Since submiss ion of this manuscript , Rubin, Sabat and Sundaralingam 
(Nucleic Acids Res .. 11. 6571-6586, 1983) have published an account of the 
very same binding of cisplatin to guanines 15 and 18 of tRNA Ph': direct 
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1. Introduction 
It is never easy to write about one's failures. This chapter 
chronicles efforts made toward the crystallographic analysis of the 
DNA-binding domain of the lac repressor protein, both by itself and in 
complex with a twenty-one base pair DNA oligomer spanning the 
repressor's consensus binding site. This project was begun in 1974 in 
this group by John Rosenberg, with the original goal of isolating, 
crystallizing and solving the structure of the entire repressor 
molecule, in complex with a DNA restriction fragment containing its 
binding site. At that time, Rosenberg et al. ( 52) were successful in 
developing a procedure for isolation of the protein in pure, stable 
form but were not successful in producing crystals of suitable quality 
for crystallographic structure analysis. My goals in this work were 
essentially the sarre: to isolate the DNA binding domain in pure form 
and then to crystallize it, both alone and in complex with its 
operator site. And likewise, I was successful at the former, but not 
the latter, task. 
The lac repress or /operator system of h coli was the first 
example of a regulatory system identified and studied in a living 
organism at the genetic and molecular level. First delineated by 
Jacob and Monod (26), as described below, it became the paradigm of 
gene regulation in a living system, and although other regulatory 
systems in both cells and viruses have since been identified and 
studied in great detail, the lac system remains the most extensively 
studied and well understood regulatory system of all. In one area of 
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study, however, it has recently been eclipsed by several other 
repressor/operator systems, and that is in the area of 
three-dimensional structural analysis. In the past few years, x-ray 
crystallographic studies have revealed at the atomic level the 
structures of the larrbda (47) and cro (4) repressors of phage lambda, 
and of the catabolite gene activator protein (36) and the trp 
repressor (54) of ~coli. In addition, the low resolution structure 
of the phage 434 repressor (3) in complex with its DNA binding site 
has been solved, and work has begun on the solution of high resolution 
crystals of the lambda repressor /operator complex (28). The 
structures solved to date have revealed a number of interesting 
details about each of these proteins, in particular that there appears 
to be a conserved structural motif present in all of them consisting 
of a helix-tum-helix configuration that is believed to represent the 
specific DNA binding site of these molecules (43, 44, 60, 62). 
Comparison of amino acid sequences of these repressors with that of 
lac as well as of a number of other sequence-specific DNA binding 
proteins has shown that this structure appears to be conserved among 
all of them and probably is a fundamental structural mechanism of DNA 
recognition ( 61). Because of the enormous body of biochemical and 
genetic information available on the lac system, a structural study of 
the lac protein and DNA would add immensely to our understanding of 
ge~ regulation at the molecular level. 
This second attempt was prompted by two developments that came 
about after the original work had been abandoned: the availability of 
a synthetic twenty-one base pair lac operator fragment, and the 
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discovery of a procedure for isolating the amino-terminal DNA binding 
region, or headpiece, of the lac repressor as a stable proteolytic 
fragment. The former was made possible by the development of liquid 
phase phosphotriester chemistry for the synthesis of DNA fragments of 
defined sequence in pure form (23), and large quantities of the 
twenty-one l::ase pair consensus DNA binding site were synthesized for 
this purpose by Dr. Peter Dembek in our lab. The latter is described 
below and made it possible to go from working on the large and 
unstable tetrameric complex that is the lac repressor, to a small, 
stable rocmomeric peptide that nevertheless possesses all of the DNA 
binding activity of the intact protein. In light of the great 
successes that were being achieved at the time with other small 
repressor proteins, it was felt that these two factors made the 
proposed headpiece/operator project, which is in fact an entirely 
different project from the original one, seem very feasible. 
This report describes the outcome of these two steps: the 
isolation of the headpiece, and attempts at crystallization of it and 
its DNA complex. The first step required the development from the 
isolation procedures then in use of a protocol that would allow the 
fragment to be isolated in high concentration and in very stable form, 
two specific requirements for the growth of macromolecules. How this 
was done is detailed below. The second step involved a number of 
trial screens for conditions under which the protein and the complex 
would yield crystals suitable for x-ray structural analysis. The 
specific conditions that were tried, the reason why they were chosen, 
and their results, are reported. Finally, an attempt at analyzing the 
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results and at making suggestions for future efforts on this system 
will b8 made, for the benefit of future workers on this project. 
-24-
2. Background 
In their study of the regulation of lactose metabolism in 
E. coli, Jacob and Monod (26) proposed a system by which the synthesis 
of the enzymes necessary for this process could be controlled by the 
presence of the metaoolized sugar. Their scheme postulated the 
existence of two distinct types of genes in the organism: structural 
genes, called z, y and a, which code for the synthesis of 
beta-galactosidase, beta-galactoside permease and beta-galactoside 
transacetylase, the three enzymes necessary for lactose utilization; 
and a new class of genes, which they called regulatory genes, whose 
function is to see that the enzymes coded for by the structual genes 
are produced only when there is lactose present to be metabolized. 
Through analysis of the types of mutants of lactose metabolism 
regulation that could be isolated, they determined that there rrn.Ist be 
controlling this system two of these regulatory genes, which they 
called i and o and to which they assigned the following functions. In 
the absence of lactose, the product of the i gene, called a repressor, 
interacts with the o, or operator gene in such a way that production 
of the three structural genes is prevented. In the presence of the 
sugar, however, the repressor would not interact with the operator, 
and the structural genes would start to be synthesized. They 
speculated that the repressor must be a protein that would interact 
specifically with a section of the E. coli DNA within the operator 
gene and in so doing would block the synthesis of the structural genes 
only when lactose was not present. But when the sugar was present, it 
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would somehow stop this interaction and free the genes coding for the 
enzymes for synthesis. 
This nodel, for what is now termed an inducible system, has since 
been shown to be the correct mechanism of control of this enzyme 
system, called the lac operon (8). The current picture is that it 
consists of a single stretch of DNA containing the above five genes 
along with another, called the promoter or p, that is the binding site 
for RNA polymerase, in the order i-p-o-z-y-a ( 38) • The i gene codes 
for the lac repressor (21), a 155,(X)() dalton tetrameric complex of 
four identical subunits (51) that binds tightly and specifically to 
the operator region in the absence of its specific inducer, the 
lactose isomer allolactose (27), but not in its presence, and thereby 
inhibits the attachment of RNA polymerase at the promoter site. This 
accordingly prevents readout of the three structural genes (22). The 
lac operator has been sequenced (20), and the actual base pairs within 
the gene to which the repressor binds have been determined by DNA 
digestion studies (20, 56) and by repressor dissociation kinetics of 
various fragments of the operator sequence ( 6) • This has shown the 
operator to consist of a pseudopalindrome of 21 base pairs, in which 
the outer twelve base pairs form a palindrome separated by a nine 
base-pair nonpalindromic region ( 6) : 
A-A-T-T-G-T-G-A-G-C-G-G-A-T-A-A-C-A-A-T-T. The monomeric repressor 
protein has also been sequenced (16), and both genetic mapping 
analysis (2, 55) and study of the effects of partial proteolysis on 
binding activity (17, 48) have shown the protein to be divided into 
two distinct functional regions: an amino terminal region, consisting 
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of amino acid residues 1 to 50, which are necessary for DNA binding 
activity, and a carboxy terminal region, residues 60 to 360, which 
binds the inducer m::>lecule and regulates DNA binding activity, as well 
as forms the tetameric complex ( 66). In addition, it has been shown 
that these two functional regions are in fact distinct structural 
regions of the protein as well, with the smaller and more mobile amino 
terminal region, or "headpiece, " being attached to the carboxy 
terminal segment, or "core, " by an extremely flexible "hinge" region 
consisting of residues 51 through 59 (64). The repressor has been 
implicated by hybridization (18) and by direct visualization studies 
( 45, 59 ) to have 222 molecular symmetry, with the core regions of each 
monomer forming the inter-subunit contacts and holding the headpieces 
outward in pairs on opposite ends of the cluster. DNA binding to this 
complex has been shown to occur through pseudosyrrnnetric binding of two 
headpieces to opposite ends of the operator binding sequence (18, 30). 
Electron microscopic studies reveal a complex in which the repressor 
just touches the operator at one edge of the tetrarner and in fact does 
so on only one side of the operator (1, 13, 24). 
How this specific repressor-operator interaction occurs has been 
a point of major interest, and research has shown that lac repressor 
in fact has two modes of DNA binding: a tight, specific binding to 
the operator site itself, and a less tight, nonspecific binding to DNA 
in general (32). Specific binding has a dissociation constant Kdi 
SS 
of 3.5 x 1013 M-l (7), and is believed to occur through 
sequence-specific interactions within the major groove of the operator 
site (33, 34, 40). Nonspecific binding, on the other hand, has a 
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Kdi of approximately 103 less and seems to occur on either the major 
SS 
or the minor groove side (12, 68), since DNA in which the major groove 
is filled with blocking groups exhibits the same nonspecific binding 
affinity as normal DNA of similar sequence ( 50). 
What is intriguing is that both of these types of binding are 
performed by what appears to be the same binding site on the 
headpiece. Numberous experiirents have attempted to probe the 
structure of bound and unbound repressor and operator, and from them 
have come the following generalizations: First of all, amino acid 
residues 1 through 20 are important for binding activity, and, in 
particular, residues 7, 12, and 17, all tyrosines, are believed to 
interact directly with the DNA in both types of binding (11, 15). 
Secondly, operator DNA is partially unwound, by either 40 or 90 
degrees, on binding to repressor ( 65), while non-operator DNA is not 
(50); but in general, no major structural reorganization of the DNA 
occurs in either type of binding (12, 25). Finally, although both of 
the headpiece binding sites (taken as pairs of headpieces in the 
intact repressor complex) and the operator binding sites should be 
symmetrical, and hence binding should be symmetrical as well, evidence 
suggests that binding to the operator by intact repressor is not 
symmetrical but in fact is stronger on one side of the operator region 
than the other ( 42). 
Lac Headpiece 
Studies of the interaction between lac repressor and lac operator 
made a significant methodological advance with the discovery by 
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Geisler and Weber (19) of a protocol for the isolation of the lac 
headpiece as a stable proteolytic fragment of the whole molecule. 
Under roc>st conditions, the headpiece region is very quickly cleaved 
from the repressor and then degraded into several fragments under even 
mild proteolytic conditions, starting in the residue 51 to 59 "tether" 
region connecting the two domains (17); as a result, the headpiece 
cannot be isolated intact. Geisler and Weber found, however, that in 
a buffer system consisting of 1 M Tris.HCl pH 7.5 and 30% glycerol, 
proteolysis stops after this first cut, and the headpiece is resistant 
to further degradation. They developed a procedure for isolating the 
headpiece in homogeneous form and showed by circular dichroism that it 
possessed a stable secondary structure. Furtherroc>re, they found that 
it was active in INA binding in filter binding assays, though it 
apparently had lost the ability to distinguish operator from 
nonoperator DNA. This made it possible to shift from study of a 
complex of four chains with 360 amino acids each to the analysis of a 
single 51 to 59 amino acid monomer, simplifying the problem greatly. 
It was soon shown by a number of techniques, such as DNA protection 
studies with dimethyl sulfate (41), circular dichroism studies of 
operator vs nonoperator binding (14) and by nuclear magnetic resonance 
studies of headpiece binding to operator-containing DNA fragments (9), 
that the headpiece still did in fact discriminate between operator and 
nonoperator binding, and that the apparent loss of specific binding 
seen in the 
affinity of 
filter binding assay was due to the greatly reduced 
7 -1 the headpiece monomer, Kd 5 x 10 M (14), versus the 
tight binding due to two headpieces in the intact repressor, Kd = 3.5 
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x 1013 M-l (7). Hence, the headpiece is a suitable system for the 
study of both specific and nonspecific binding. 
Analysis of the headpiece by a number of methods has revealed the 
following information about it and its interaction with DNA. First of 
all, the protein does make both specific and nonspecific interactions 
with DNA, and in a manner that is virtually, but not precisely, the 
same as when it is part of the intact repressor. In both, specific 
contacts are made by residues Tyr 7, Tyr 17, Tyr 47 and His 29, as 
shown by the effects of iodination on repressor binding (15), by N}R 
effects seen on headpiece binding to poly d(AT) (11, 25) and to a 
synthetic operator fragment (53), by UV titration of 
operator-containing DNA (29) and by fluorescence and circular 
dichroism (14, 57). Furthermore, these contacts are sensitive to 
ionic strength and disappear in salt concentrations of 120 mM or 
higher (9, 29, 57). 
The protein by itself has been found to form a stable, though 
flexible, structure in solution. NMR studies of the headpiece have 
shown that it possesses the same overall structure, both when attached 
to the repressor and as a separate entity (10, 49, 64). Further, 
thermal melting curves have shown that this structure is stabilized by 
salt, with P04 ion being a mJre effective stabilizer than NaCl (58, 
63, 67). Unfolding and renaturation of the protein, both by 
temperature and by change in pH, is a srrDOth and continuous process, 
with no specific melting temperature, indicating that the protein 
possesses a flexible structure unlike those of IIDSt globular proteins 
(49, 58, 63, 67), though circular dichroism studies have indicated 
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that the protein does in fact possess an extensive secondary structure 
(63). Recently, the headpiece has been studied by 2D NOE Nl-R 
techniques, and the resonances of all hydrogen atoms have been 
assigned. Based on this information, it was possible to determine the 
precise secondary structure and all close contacts occurring within 
the molecule, and by combining this information with the necessary 
nvlecular constraints required of a protein, a structure of the 
fragment in solution has been deduced (31, 69, 70, 71). In this 
nvdel, an illustration of which is given in Reference 69, residues 6 
to 15, 17 to 25 and 35 to 45, respectively, form three alpha helices, 
with bends at residue 16 and in in the region 26 to 34. A hydrophobic 
core is formed by residues Val 19, Val 20, Val 23, Val 24, Leu 6, Leu 
45, Ala 10, Ala 41, Met 42 and Tyr 47. Tyrosine 7, Tyrosine 17 and 
His 29 point to one side of the structure, as expected from their 
known involvement in DNA binding. Also, as expected from sequence 
homology studies (61), helices one and two form the helix-tum-helix 
nvtif seen in the other repressor structures, and the overall 
structure is homologous to that of the lambda repressor ( 31). 
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3. Lac Headpiece Isolation 
a. Earlier Protocols 
At the time that this project was begun, there were several 
protocols in the literature for the isolation of the headpiece 
protein. Each had its own drawtecks in the preparation of material 
for crystallization purposes, but all taken together provided a basis 
for the protocol that was finally adopted. These procedures, their 
advantages and disadvantages will be discussed in turn, to show the 
steps leading to the strategy that was finally settled on, and its 
results. 
The first of these was the original isolation procedure of 
Geisler and Weber (19). This consisted of digestion of repressor with 
protease in 1 M Tris.HCl pH 7.5, 30% glycerol buffer, followed by two 
sizing colunm steps, a Sephadex G-150 step and a Sephadex G-25 step. 
The strategy was to separate the headpiece and tether protein from the 
repressor, core and protease during the first step, and then to 
separate the headpiece from the tether during the second. The 
procedure has several problems. The first of these is the rather 
crude separation achieved by the choice of sizing resins, in that the 
headpiece is entirely included by the first and entirely excluded by 
the second, so that no separation of material of similar molecular 
weight, such as partially digested headpiece protein or similar 
molecular weight contamination in the repressor or protease 
preparations, is achieved. The second problem is the lack of any way 
to distinguish active headpiece from material that is intact but 
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inactive tecause of denaturation. The third problem is the production 
of a very dilute product, which ideally should be as concentrated as 
possible for use in crystallization trials. And the last difficulty 
is the lack of any scrupulous method of rem::>ving residual protease 
activity, critical for material that must be maintained in solution 
for long periods of time during crystallization. 
An entirely different approach was taken by Buck et al. (11). 
Their procedure involved separation by use of the fact that active 
headpiece binds to phosphocellulose. Core protein and proteases such 
as trypsin and chymotrypsin are not retained under these conditions. 
Their protocol used a phosphate buff er gradient on a colu!llll of Whatman 
P-11 resin as their first and only separating step. Following this, 
they used a procedure, first developed by Otsuka and Price (46) to 
stabilize DNase I preparations, in which the material is passed 
through a Sepharose colu!llll to which lima tean trypsin inhibitor 
protein has been linked covalently, making a specific protease 
affinity colu!llll. As used by Otsuka and Price, the colulllll made stable 
for days DNase I preps, which by conventional purification methods 
lost activity in solution after only a few hours because of residual 
protease activity. Using this strategy, the final product of Buck et 
al.then represents a fraction of stable, purified binding activity, 
consisting mainly of the headpiece protein. The problem with this 
sch:!me is the lack of a size separation step, so that any residual 
repressor protein or any other contaminants that bind to the ion-
exchange resin under these conditions also would be present in their 
final product. And, as with the procedure of Geisler and Weber (19), 
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the product would be dilute as well. 
A third procedure was used by Arndt et al. (5), which combines 
many of the strengths of the other two into a more lengthy and 
rigorous purification scheme. Following digestion, the material was 
first separated on phosphocellulose with a step gradient, giving a 
concentrated fraction containing the binding activity. This then was 
fractionated on Sephadex G-75 to separate out the headpiece from other 
size contamination present, and, finally, the material was 
concentrated by loading and eluting it on another phosphocellulose 
column. The result was a highly purified protein possessing full 
binding activity. 
The only drawback was the lack of a step to reIIXJve the residual 
protease activity. 
The protocol that was finally settled on takes advantage of the 
best features of all these methods to produce a product that is of 
high purity, possesses full DNA binding activity as assayed by its 
ability to bind to phosphocellulose, is highly concentrated, and is 
scrupulously protease-free. In this procedure, the proteolytic digest 
is first passed through a lima bean trypsin inhibitor Sepharose 
affinity column while still protected in Tris/glycerol buffer, in 
order to remove the bulk of the active protease before this protection 
is lost. Then it is fractionated on phosphocellulose in a step 
gradient, to remove most of the nonbinding protein present, followed 
by passage through a second lima bean trypsin inhibitor column to 
remove the last traces of protease activity. The material is then 
size-fractionated on Sephadex G-50 to reIIXJve any residual repressor 
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and any other higher or lower molecular weight material that might 
have bound to the ion exchange colunm, and finally is concentrated by 
passage through a second phosphocellulose column. The results are 
described below. 
b. Experimental: Repressor Isolation 
Lac repressor is isolated from the overproducing strain BMI-174-14 
(iql, Reference 39). This strain contains the gene for the repressor 
protein coupled to a lysogenic phage lambda expression vector system. 
Induction of the phage by temperature shock causes the cells to 
express the gene for the repressor and to produce the protein in high 
quantities. The cells are grown in LB broth, which consists of 10 g 
Bacto-tryptone, 5 g Bacto-yeast extract (both Difeo) and 10 g NaCl per 
liter, adjusted to pH 7.5 with NaOH (35). The bacteria are grown in 
l(X) liters of medium starting from a two-liter overnight starter 
culture. The cells are initially grown at the permissive temperature 
of 32°C, under which the vector is not expressed, to an A6CX) of 1.2 
a:>. The culture is then heated quickly to 45°C for fifteen minutes, 
which causes induction of the vector, resulting in production of the 
0 protein at high levels in the cells, followed by growth at 35 C for 
four hours to allow the repressor gene to be expressed. Cells are 
isolated by centrifugation and then quick-frozen with liquid nitrogen 
and stored at -70°C until use. A 100-liter fermenter run typically 
yields 3CX) grams of wet cell paste. 
The repressor protein is isolated by the method of Rosenberg et 
al. (52) with minor modifications. The 300--gram frozen cell pellet 
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is broken into small pieces and lysed by addition to 200 ml of CSB 
buffer (0.2 M Tris.HCl, 0.2 M KCl, 10 rnM MgAc2 , 0.3 mM dithoithreitol 
(DTT), 5% (w/w) glucose, 0.1 rnM orthonitrophenylfucose (ONPF) and 0.05 
mg/ml phenylmethane sulfooyl fluoride (PMSF), pH 7.75 at 4°C) 
containing 10 mg of DNase I and 10 mg of hen egg white lysozyme, at 
4 °c. The lysate is further broken up by mixing for brief intervals in 
a blender, then allowed to stand for an hour and a half, with 
additional blending every thirty minutes ; the mixture is thin and 
homogeneous at the end of this period. The pH is readjusted to 7.5 
with KOH, and the solution spun for two hours at 15,000 rpm at 4°C in 
a Beckman Type 19 rotor. The clear, greenish supernatant is decanted 
off, and solid ammonium sulfate added to it to 33% saturation. The 
mixture is allowed to precipitate overnight at 4°c with gentle 
stirring. 
The precipitate is spun for two hours at 8,000 rpm at 4°C in a 
Sorvall GS-3 rotor. The pelleted material is resuspended in 100 ml of 
0.075 KPG (75 mM KP04, 0.3 mM D'IT, 0.1 mM ethylenediamine tetraacetic 
acid (EDTA), 5% glucose (w/w) and 0.05 mg/ml PMSF, pH 7.4 at 4°C) and 
dialyzed overnight against 6 liters of 0.075 KPG; all at 4°C. 
The slightly cloudy dialysate is diluted as necessary with 0.0 
KPG (0.075 KPG buffer without KP04) until its conductivity matches 
that of 0.075 KPG, and then spun for 3.5 hours at 35,000 rpm at 4°c in 
a Beckman Type 35 rotor. The clear supernatant is loaded onto a 400 
ml bed volume coluIID1 of P-11 phosphocellulose ion exchange resin 
(Whatman), which is first equilibrated by washing with several volumes 
of 0.075 KPG. After loading, the coluIID1 is washed with 0.075 KPG 
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until the A280 is reduced to 0.1 AU, and then the repressor is eluted 
with a 1500 ml linear gradient of 0.075 to 0.4 KPG buffer. The colunm 
is rronitored by lN absorption, and the peak fractions assayed for 
isopropyl thiogalactoside ( IPTG) binding activity ( 51), before pooling 
based on the latter assay. The protein is then precipitated by 
addition of 0.1 KPG saturated with annnonium sulfate to 40% saturation, 
allowed to sit for one hour at 4°C with gentle stirring, and then 
0 pelleted for one hour at 8,CX)() rpm at 4 C in a Sorvall GS-3 rotor. 
The pelleted material is resuspended in 1 M Tris.HCl, pH 7.5, 30% 
(vol/vol) glycerol, 1 mM IDI'A and 0.3 mM D'IT and dialyzed overnight 
against one liter of the same, all at 4°C. The final product is 
aliquotted into 1.8 ml portions and quick-frozen in liquid nitrogen, 
for storage until needed. Typical yields are 300 mg of final product 
at approximately 15 mg/ml. 
c. Lac Headpiece Isolation 
Lac headpiece is isolated by a combined protocol of Buck et al. 
(11) and of Arndt et al. (5). Alpha-chymotrypsin at approximately 7 
mg/ml in 1 M Tris.HCl pH 7.5, 30% (vol/vol) glycerol, 1 mM IDI'A, 0.3 
mM IYIT and 1 mM toslylysine chloromethyl ketone (11..CK) is preincubated 
for twenty minutes at 20°c, in order to eliminate any tryptic activity 
present in the protease. It is then added to lac repressor protein, 
isolated as described above, in the same final buffer plus 0.25 mM 
'Il.CK, to a level of 1% (wt chymotrypsin/wt repressor). The solution 
is allowed to incul:ate for three hours at 20°C with slow end-over-end 
mixing in a polypropylene tube. At time, PMSF is added to 1 mM, and 
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the digest allowed to incul::ate for an additional twenty minutes. 
The digest is passed through a 9 ml volurre of lima bean trypsin 
inhibitor-Sepharose, prepared as described by Otsuka and Price, in 
Tris/glycerol buffer at 20°c. The eluted peak fractions are cooled to 
4°C and diluted by slow addition of 12.S volumes of 0.05 K buffer (SO 
mM KP04 pH 7.4, 1 mM EDTA, 0.1 mM JJIT, 0.1 mM PMSF). The sample is 
then loaded onto a small P-11 coluIIITT (alx>ut 1.5 times the starting 
volume of protein), which is pre-equilibrated with the sarre 1:12.S 
mixed buffer. The column is washed with alx>ut five more volumes of 
the buffer, then eluted with 0.6 K buffer (0.6 M KP04 pH 7.4, the rest 
as above), and the peak fractions of the step gradient pooled. This 
peak is passed through a 2 ml volume lima bean trypsin 
inhibitor-Sepharose and the peak isolated; all at 4°C. 
The peak is next loaded onto a 2.5 by 100 cm coluIIITT of Sephadex 
G-50 Fine (Pharmacia), which has been equilibrated with 0.06 K buffer 
at 4°C, and fractionated. This yields three peaks: a leading peak, 
containing the fully excluded material; a trailing peak of the fully 
included matter; and a middle peak, centered in the sizing range of 
the resin, containing lac headpiece (Figure 1). The pooled fractions 
of this peak are loaded onto a 15 ml column of P-11 equilibrated with 
0.06 K buffer, also at 4°C, washed with several more volurres of the 
buffer, and then eluted with 0.6 K buffer in a step gradient. The 
final material is quick-frozen in liquid nitrogen and stored in 1N2 • 
To concentrate the material further and to put it into a buff er 
suitable for crystallization, the protein solution is dialyzed 
overnight against 1 liter of 100 mM NaCl, 10 mM Na cacodylate pH 7.5, 
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0.1 rnM EDTA, 0.1 rnM DIT and 0.1 rnM PMSF at 4°C, in Spectrapor 6, 1,000 
MWCD dialysis tubing (Spectrapor Medical Industries), and then 
dialyzed against the sarre buffer containing 25% (w/vol) polyethylene 
glycol (PEG) 20,000, until the desired concentration is reached. The 
final material is dialyzed against one IIDre liter of the original 
buff er without PEG and finally aliquotted into 100 microliter portions 
and quick-frozen in liquid nitrogen until use. Typical yields from a 
300 mg repressor prep are 10--15 mg of final headpiece protein at 6 to 
7 rrg/ml. 
The course of the purification can be seen in the gel shown in 
Figure 2. The original repressor is shown in lane 1, and all 
subsequent steps are shown in proportional volurre loadings, except as 
noted. Lane 2 shows the material after digestion, which appears to be 
essentially complete. Column 3 shows the digest after passage through 
the lima bean trypsin inhibitor-Sepharose column, where it can be seen 
that none of the headpiece protein has been retained. 
Lanes 4 and 5 show the load/wash and high-salt elution peaks, 
respectively, of the first P-11 column step. The core and roc>st of the 
other contaminant peaks are seen to have been removed by this step, 
although sorre high IJDlecular weight contaminants still remain. The 
headpiece itself also seems to have been separated in good yield, 
although sorre apparently has washed through; this may be inactive 
material, or simply some that was not retained on the column under the 
conditions necessary to pass the core. 
Lanes 6 and 7 show the fully excluded volume and the headpiece 
fractions, respectively, of the Sephadex G-50 column; these 
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correspond to peaks 1 and 2 of Figure 1. While sorre headpiece has 
eluted with the excluded volume, due to the width of the peak on this 
resin, virtually all has come through as the second peak, and all of 
the high molecular weight contaminants have been removed. 
Lane 8 shows the high-salt elution peak of the second P-11 
column. This shows that the activity of the fraction isolated has 
been preserved, and that the yield is still high; this was also 
confirmed by monitoring the lN absorbance of the load/wash step. 
Lane 9 shows the final, concentrated material after dialysis 
against PEG 20,CX)(). Once again, no substantial losses are seen. 
The activity and stability of the isolated headpiece protein are 
demonstrated by the following results. First, active headpiece is 
known to bind to P-11 cellulose phosphate under the conditions used in 
the prep, whereas inactive headpiece does not (5); therefore, the 
material, at least as far at the final dialysis step, is by this 
criterion, active headpiece. Secondly, stability was confirmed by 
incubation of a 2.5 times proportional volurre load of the product at 
4°C for 14 days in the final storage buffer; this sample was then run 
on the gel shown in Figure 2 as lane 10. The band is at the expected 
intensity on the gel, and furthernnre, no lower m::>lecular weight bands 
representing partially digested headpiece are seen on this gel system, 
which is able to resolve material as small as 1,400 dalton as a sharp 
band. 
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4. Crystallization Trials 
a. Background 
The growth of large, single crystals of a material of suitable 
quality for diffraction analysis is the essential first step in any 
x-ray crystallographic study. While this is a rather obvious point, 
it is a crucial one for the course of any such analysis, because for 
very many compourrls that have been taken up for study by 
crystallographers over the years, the analysis has ended at this 
stage, often after many IJPnths or even years of effort, because of a 
failure to produce the necessary crystals. The variable and seemingly 
random nature by which some macronnlecules will produce crystals and 
others will not is a well-known phenomenon and has shrouded the 
crystallization process with an air of mystery and mumbo-jumbo that it 
probably does not deserve. For this reason, a discussion of the 
theory and practice of crystallization will be given, followed by a 
description of which methods were tried on the two molecules being 
studied and what results were obtained. This will serve two purposes: 
first, to explain the reason behind the particular systems that were 
tried, and, second, to serve as a guide to others who might work on 
this project as to what has been tried and the results of these 
trials. 
The crystallization of a macronolecule is the process of causing 
a solution of that molecule to go into the solid state in the form of 
a stable, repeating lattice of the nnlecules in space. This process 
has been discussed from both a theoretical and a practical point of 
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view by McPherson (37), who considers it in terms of the 
thermodynamics of a transition from the solution to the crystalline 
state. In this view, whether a macromolecule is in solution or not 
depends on the overall free energy of the system under a given set of 
conditions; it is ooly when these conditions favor interactions 
between solute molecules over solute-solvent interactions that the 
transition to the solid state will occur. Whether this transition 
results in well-ordered crystals or simply amorphous precipitate 
depends on the nature of these solute-solute interactions, and 
McPherson discusses them in terms of the effects of counterions, 
ligands and various other parameters, as they may affect the overall 
free energy of the crystal lattice. These considerations favor the 
crystalline state as that of minimum free energy; but it is up to the 
nature of the components of the system to determine whether this 
minimJm can actually be achieved. 
Another way to consider this problem is in terms of how well the 
components of the system are able to form a repeating lattice. As in 
a brick wall, the rrost stable lattice can be forI!lt2d from molecules 
which, like bricks, are sufficiently rigid and uniform in shape to 
form a regular, repeating structure. This implies that the 
macromolecules must be able to interact with each other in a regular, 
stable manner so that they form an array that possesses precise 
translational repeats along three orthogonal axes in space. 
Therefore, macromolecules which do not possess a rigid, regular 
structure, or that are not capable of forming regular contacts that 
are conducive to the establishment of such an array, will not be able 
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to form good crystals. For this reason, it is probably not a 
coincidence that the proteins that give the most stable, 
high-resolution crystal forms are proteins such as the various 
proteases, many of their macromolecular inhibitors, and a host of 
other largely secretory proteins that possess very rigid, usually 
highly crosslinked structures. Conversely, a number of other 
proteins, such as recA protein (D Goodsell, personal communication), 
which otherwise might serve as very stable building blocks for crystal 
lattices, do not do so in practice because they naturally interact to 
form complexes that do not possess a suitable translational repeat. 
As will be discussed, this requirement of a rigid, stable structure 
for lattice formation is probably a major reason for the failure of 
the lac headpiece protein itself to crystallize, while in complex with 
its DNA operator site it appeared to give quite different results. 
From a practical point of view, finding the right crystallization 
conditions for a macromolecule generally takes on the strategy of 
starting with a general set of conditions under which the fOC)lecule 
will come out of solution, and then refining these to see if they can 
be made to bring about the desired crystal growth. The first step is 
to find a precipitant, or some condition under which the molecule will 
come out of solution. This can be as simple as concentration of the 
solution by dialysis or even by evaporation, but the usual procedure 
is to use a precipitating agent. As set forth by McPherson, these 
fall into two general categories: organic precipitants, ranging from 
mild solvents such as 2-methyl-2,4-pentanediol (MPD), to such 
heavy-duty organic solvents as acetone or toluene; and salts, usually 
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polyvalent, always very concentrated, with arrnnonium sulfate, anunonium 
phosphate and ammonium citrate being three very popular and successful 
examples. Their purpose is to prorrote interaction between oolecules 
by lowering the dielectric constant of the medium and/or by helping to 
crosslink the molecules together. The ideal precipitant must achieve 
these objectives while not denaturing the macromolecule in the 
process. The general procedure for testing them is to perform an 
initial precipitation trial of the macromolecule with a number of 
them, and, tased on the results, to select as many as can be tested in 
further crystallization trials. 
Once a series of precipitants has been selected, the next step is 
to choose a crystallization method. Crystallization requires that 
some parameter or parameters of the system can be varied in a 
controlled manner, so that the macromolecule can be brought to the 
proper state of precipitation to allow crystallization to occur 
preferentially over amorphous precipitation. Again, a number of 
methods exist, ranging from crude bucket methods of adding precipitant 
to large amounts of material, to a number of very sophisticated 
microscale techniques that can be used when only small amounts of the 
material are available (which is almost always the case). These 
latter methods generally fall into one of two categories of how the 
conditions are varied: namely, by vapor phase equilibration or by 
dialysis. The former methods all work by equilibrating a small sample 
of the macromolecule solution, usually a drop, against a larger 
reservoir of solvent at a different concentration, all in a sealed 
system. Over time, the activity of the macromolecule-containing 
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solution becomes equal to that of the solvent reservoir, and, by 
judicious control of the starting activities of the two solutions, the 
sample can be taken very slowly through the desired activity range for 
crystallization to occur. Taking such forms as the spot plate and the 
hanging drop, these have been very successful in producing crystals of 
compounds in a number of cases. Their advantages are that they are 
easy to set up and maintain, and in suitable configurations allow for 
easy examination of the solutions during crystallization. Their main 
disadvantage is that they allow only volatile components of the system 
to be varied, leaving salts and other nonvolatile components of the 
system unchanged. In addition, volume change is a necessary result of 
equilibration, with the result that the concentrations of all of the 
nonvolatile components of the system change over the course of the 
crystallization, making control of the individual components 
impossible. 
A different technique that overcomes these disvantages is 
microdialysis, in which the macromolecule solution is dialyzed in a 
sT1Ell cell against a larger reservoir of precipitant. Again, by 
judicious choice of the two solutions, very precise control of the 
conditions in the sample can be achieved. The main advantage is that 
any of the components small enough to pass through the membrane can be 
varied at will, while the volume of the sample can be maintained 
constant. This feature allows precise control of these conditions 
during the course of the crystallization. The disadvantages are that 
setup is in general more difficult, and that examination of the sample 
is usually much more difficult than with other methods ~ no small 
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consideration when one is searching for microcrystals. 
The general wisdom is that once a set of crystallization 
conditions has l:Een found for a material, any of these techniques can 
be used to produce crystals by suitable adjustment of the conditions. 
However, in practice, it turns out that certain techniques often 
produce bigger or better crystals, or produce them faster or more 
repeatably than do others. And so, it is usually necessary to try a 
series of techniques with a given set of conditions until the best 
ones for the particular compound can be found. 
Once a precipitant and a methodology have been selected, the 
final step is to vary the system pararreters until crystallization is 
achieved. Besides the two major parameters already discussed, there 
are two others that need to re varied: the presence of counterions 
and other ligands in the solution, and the solution pH. The former 
can include rronovalent, divalent and higher anions and cations, which 
may stabilize the structure, aid in forming crosslinks between 
adjacent molecules in the crystal lattice, and so on; stabilizers, 
such as reducing agents, antimicrobials, and chelating agents, which 
help to maintain the integrity of the macromolecule; various ligands 
that the macromolecule may bind to specifically, whose presence may 
also stabilize the compound's structure; and, frequently, other 
components that have no obvious role in the crystallization process at 
all, but which may help to promote, or even 1:E essential for, 
crystallization to occur. The latter parameter, the solution pH, is 
almost always a critical variable for crytallization, as most 
macromolecules will crystallize only over a certain range of pH 
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values, often because they frequently are active and/or stable only 
over this range. Ideally, the range of stability and the range of 
crystallizability should overlap, but occasionally this is not the 
case. 
As the range of possible combinations of these variables is 
essentially infinite, the screening process for the right combination 
of parameters necessary to produce crystals can be endless or at least 
frequently seems to be. The one saving grace of this is that, in 
general, crystallization can be achieved in steps, by a series of 
successive refinements on a promising starting set of precipitating 
agents and a method of crystallization by systematic variation of the 
various parameters. The nightmare case of there being one and only 
one set of conditions under which the macromolecule gives crystals, 
all others giving no result, seems to be more the exception than the 
rule. Nevertheless, the right conditions may be sufficiently 
stringent that they will be found only after long and arduous 
searching. The best strategy is to try as many initial conditions as 
possible, and then based on the results to refine the system 
parameters of those giving the rrost promising signs until suitable 
crystals are produced. The important thing, and the one that probably 
is the reason that at least some macromolecules are never successfully 
crystallized, is to keep an open mind on which sets of conditions are 
pursued and not to prejudice the choice of these conditions 
prematurely. 
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b. Headpiece Crystallization Trials 
As has been described, the lac headpiece is a small protein, 
consisting of a loose association of three helical units that probably 
are held together by rather weak interhelical interactions only. The 
observations indicating that it can be continuously denatured and then 
renatured into what seems to be a well-defined structure by a variety 
of methods suggests that suitable crystallization conditions would be 
those that are mild and stabilizing. Therefore, high-salt conditions, 
which have been found to be necessary to preserve headpiece structural 
integrity in solution, or ones involving only mildly denaturing 
organic precipitants, would seem to be the best options to explore for 
crystallization. 
A series of mild organic precipitants and salts were tested for 
their ability to precipitate the protein; the results of this screen 
are listed in Table 1. All of the organic precipitants tried, which 
were MPD, several different sizes of polyethylene glycol (PEG) and 
ethanol, were able to cause precipitation, either as amorphous 
precipitate or as a fine oil; with one of the PEGs, PEG 600, the 
precipitate in fact appeared microcrystalline. Of the salts tried, 
all of the trivalent salts induced precipitation, while none of the 
monovalent or divalent salts would do so. Based on these results, 
MPD, PEG, ammonium sulfate, ammonium phosphate and ammonium citrate 
were chosen for use in subsequent trials. 
Crystallization trials were carried out using three 
microtechniques: vapor diffusion in spot plates; vapor diffusion in 
hanging drops; and microdialysis in Zeppezauer tubes. The various 
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setups tried and the specific conditions employed, along with the 
results of each of these trials, are described in detail in Table 2. 
The results of these screens can be surrnnarized as follows: 
1) MPD: The protein either oiled out of solution or precipitated 
under all conditions tried. Several trials at pH 7.0 using various 
salts as counterions occasionally gave what looked like microcrystals, 
but nothing that was reproducible. This series was not extensively 
pursued. 
2) PF.G 600: The protein either remained in solution or formed 
oils in the initial pH screens. This series was also not extensively 
pursued. 
3) Amnonium Sulfate: Trials at pH 5 gave nothing but oils and 
were not pursued further. Trials at pH 7 and 9 gave fibrous 
microcrystals after first oiling out, and a number of screens in this 
pH range were tried. Using [x)th microdialysis and vapor diffusion 
techniques, these latter trials gave only oils along with several 
varieties of patchy, nultinucleated microcrystals, [x)th using the salt 
alone and in conjunction with a series of other monovalent, divalent, 
and trivalent salts. 
4) Amnonium Phosphate: In the initial pH screens, trials with 
the protein using the salt alone gave oils over the entire pH range 5 
to 9. A number of screens were then tried using the salt in 
ccnjunction with other salts, as with the arrnnonium sulfate series; 
these trials gave cnly oils or multinucleated fibers with all 
conditions tried. 
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5) Ammonium Citrate: Again, initial screens at pH 5 produced 
only oils, and so this pH range was not extensively pursued. At pH 7 
and 9, trials with the salt alone gave precipitates, but in 
ccrijunction with a number of other salts, a several of these trials 
gave rather similar results consisting of the appearance of numerous 
microcrystals alcrig with a characteristic "skinning over" of the 
surf ace of the spots in vapor diffusion trials. These were the most 
promising results achieved with lac headpiece, and this series was the 
rrost extensively pursued of all. However, no large crystals ever 
resulted using all of the conditions tried. 
c. Headpiece/Operator Crystallization Trials 
Trials were also carried out on the protein complexed with a 21 
base-pair synthetic operator site of sequence 
A-A-T-T-G-T-G-A-G-C-G-G-A-T-A-A-C-A-A-T-T. This sequence is a 
pseudopalindrome, in which the first and last six base-pairs form a 
perfect palindrome, and the central nine a partial palindrome between 
bases 8 and 14 and 10 and 12 (numbering from left to right). As 
described above, numerous studies have indicated that the headpieces 
make contact with the operator at the two palindromic ends, so that 
there would be two headpieces bound per operator. Headpiece binding 
is known to be abolished by high salt, and so crystallization trials 
were designed that used the organic precipitants MPD and PEG in the 
presence of low to moderate amounts of salt exclusively. 
The results of these trials are shown in Table 3. The initial 
results with PEG were encouraging, but further trials with it were 
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suspended after crystals were found on the first screen with MPD. 
These crystals were rectangular, and characteristically twinned, with 
two crystals growing end-on-€nd and inclined at about ten degrees to 
each other with respect to the long axis of each, making them look 
like boomerangs. Each half would light and extinguish as a single 
crystal and was usually brightly colored under polarized light, 
probably due to birefringence. The largest of these ~asured up to 
0.3 mn long but less than 0.05 mm wide. In addition to this form, a 
second, much smaller but apparently untwinned form of the crystals was 
also seen. These were characteristically cubic chunks, which also 
would light and extinguish singly and which were also colored under 
polarized light. Unfortunately, the largest of these were less than 
0.05 mm on edge, and no larger ones could be produced. 
Attempts were made to take x-ray photographs of these crystals to 
see if they were ordered or not. The crystals were extrerrely fragile, 
and it was not possible to mount them without causing at least some 
damage during the nounting and drying procedures. The largest of the 
twinned form of the crystals were mounted in glass capillaries, and 
several of these that could be nounted without too extensive damage 
were photographed on an Eliott GX-6 rotating anode x-ray generator 
producing copper radiation. Unfortunately, all of these crystals 
melted before they could be photographed, despite efforts to cool them 
using a cold stream device. Efforts to produce IIX)re of these crystals 
failed before the project was finally abandoned. 
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5. Conclusions 
This chapter has reen written with two main objectives in mind. 
The first is to describe the work that has reen done in an attempt to 
carry out a structural analysis of the lac headpiece, both by itself 
and in complex with its DNA binding site. The second is to act as a 
bridge retween the previous stage of this work, involving the original 
attempts to study the whole repressor, and the next stage, which will 
involve the structural solution of the headpiece in complex with sorre 
variant of its operator site. For this reason, a few points will re 
discussed about the results achieved here and a few suggestions made 
for future efforts, as a guide to the next generation of workers on 
this project. 
First, the work has shown that it is possible to isolate the 
headpiece protein as a stable species in a form pure enough and in 
quantities sufficient for use in crystallization trials. The prep, 
however, is long and tedious, and the quantities of material isolated 
in the end are smaller than one would ideally like to achieve, in 
fact, so ruch so that this was very rruch the limiting step in the 
number of crystallization trials that could re carried out with the 
protein. Much of this is simply a consequence of the fact that the 
headpiece is such a small part of the whole repressor, with the result 
that even the maxirrum theoretical yield of lac headpiece is only one 
seventh of that by weight of the starting material. When losses 
inevitable in each step of the purification are included, the final 
yield is considerably less than that. A few changes in the isolation 
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protocol might lead to better results. One would be the inclusion of 
the final sizing step in the repressor isolation protocol. The crude 
repressor used as starting ma.terial here still contains so11E 
contaminants; while these are removed in subsequent steps, some 
traces, which might affect attempts at crystallization, may still 
remain in the final headpiece product. 
Another would be the use of a different protease for digestion of 
the repressor. Chymotrypsin was chosen here for two reasons. The 
first is that it ma.kes only one cut in the repressor, giving a 
homogeneous headpiece product. Other proteases, such as trypsin, make 
multiple cuts in the tether region, giving mixed products that are 
difficult to separate. The second is that chymotrypsin can be removed 
completely from the prep by means of the lima. bean affinity column 
used; other proteases that also give single cuts, such as clostripain 
and papain, cannot, ma.king it more difficult to assure that the final 
product is in fact stable and protease-free. Unfortunately, for some 
reason chymotrypsin seems to lead to sma.ller yields of headpiece than 
do these other enzymes, possibly due to some additional proteolysis of 
the headpiece peculiar to this enzy11E (F. Buck, personal 
communication). And so, the finding of some other protease for use in 
the digestion step, preferably one for which an affinity column or 
some other means of efficiently removing it could be used, might 
result in higher yields of the headpiece protein. 
A third improvement might be to circumvent the proteolysis step 
altogether by constructing a plasmid vector containing the gene for 
direct synthesis of the headpiece. Since the lac headpiece is the N 
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terminus of the repressor, the protein synthesized by this gene would 
fold itself correctly during synthesis and would be active in DNA 
binding. By cloning rmlltiple copies of the gene into a 
high-efficiency expression vector and inserting the vector into a 
suitable host, it would be possible to isolate the protein in high 
yield, using a nuch faster combined prep. The technology to do so by 
genetic engineering techniques is well developed, and the potential 
benefits of being able to produce the protein by this shortcut method 
are obvious. 
The second point is the question of whether the headpiece protein 
can be crystallized, and how this might be done. The crystallization 
screens described all yielded negative results, though sorre of the 
precipitants tried, particularly ammonium citrate, gave preliminary 
results that were rather encouraging. The problem seems to be that 
the protein by itself does not possess the rigid, compact structure of 
proteins that do crystallize well, such as the various proteases and 
inhibitors, many of the metabolic enzymes such as the cytochromes, and 
so on, which can pack together to form tight lattices because of this 
internal rigidity. Instead, it is a fairly loose association of three 
helices, held together by only a few weak hydrophobic contacts, which 
can unfold and refold very easily, making the structure very unstable 
and the protein a poor candidate for crystallization. What is needed 
is something that will stabilize the headpiece structure enough to 
allow it to form a tight lattice. Some of the counterions tried 
seemed to give better results in forming microcrystals than did 
others, and further effort in crystallization seems in order. One 
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promising counterion would be Tris buffer, which is the stabilizing 
agent of the protein in the isolation procedure. Geisler and Weber 
(19) showed that the protective effect of their Tris/glycerol buffer 
system against proteolysis was due specifically to the presence of the 
Tris cation. It is possible that in a similar system, using one of 
the organic precipitants such as MPD in place of glycerol, this 
stabilization might make the protein rigid enough to allow it to form 
a crystal. This counterion was n=ver tried with the headpiece because 
of known problems of Tris buffer's crystallizing out in systems using 
organic precipitants (M. L. Kopka, personal comrrunication). However, 
it has been used in other crystallization systems successfully 
(Reference 37) and might be pursued at some point in the future. 
A third and final point, probably the one of greatest interest, 
is that of cocrystallization of the protein with some form of its DNA 
binding site. Preliminary results with the 21mer operator using MPD 
have been extremely encouraging, and we hope that some refinement of 
conditions with this system would produce crystals large enough and 
stable enough for diffraction analysis. Another approach would be to 
vary the sequence of the DNA binding site, with the aim of making an 
oligomer which would pack to form a strong lattice, allowing the 
protein to "go along for the ride" on the nucleic acid. Impressive 
results have been achieved using this approach by Pabo and coworkers 
with the larrbda headpiece. They found that either a 17 or a 23 
base-pair operator site in complex with their protein gave only 
microcrystals, while a 20mer gave large crystals which diffracted to 
better than 2.5 Angstrom resolution. Their analysis of these crystals 
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showed that the DNA helices in it pack end-on-end to form continuous 
helices throughout the crystal, and that at 20 base-pairs the repeat 
is in phase with the ten base-pairs per turn of B-DNA, allowing the 
repeat to match the crystal lattice (Reference 28). The 21mer, by 
this criterion, would be one base-pair tcx:> long for ideal B-f orm DNA; 
therefore, the use of a sequence one base-pair shorter might yield 
better results. 
Another problem with the 21mer being used is the location of the 
headpiece binding sites on the helix. As described above, the 
headpieces are thought to bind to the six base pairs of either end of 
the 21mer. Therefore, the presence of the headpiece protein bound to 
these sites on the DNA might interfere with the establishment of this 
end-on-end packing in the crystal. In addition, the fact that there 
are actually two headpiece binding sites per DNA helix makes the 
combined structure a complex between three independent components, 
which is quite complicated. A possible solution to this would be to 
use a shorter DNA sequence, containing only one headpiece binding 
site, which also could form the end-on-end stacking arrangement 
described. One such sequence might be A-C-A-A-T-T-G-T-G-C, which is a 
ten base-pair palindrome containing the A-A-T-T-G-T headpiece binding 
site as its center, surrounded by a two base overlapping end. This 
overlap could base-pair with adjacent helices, to form continuous ten 
base pair per turn helical repeats in a crystal lattice, as in the 
20mer used by Pabo and coworkers (28). The basic unit would then 
contain one headpiece and one DNA binding site, making the structure 
an ideal size for crystallographic analysis. 
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Table One: Headpiece Precipitant Trials 
Trials were performed by placing 10 rnicroliters of headpiece 
protein at a concentration of 6-7 ng/ml in a buffer containing 100 mM 
KCl, 10 mM Na cacodylate pH 7. 5, 0 .1 mM dithiothreitol, 0 .1 mM 
phenylmethane sulf onyl chloride, 0.02% Na azide in a depression slide, 
and adding the precipitant at the given starting concentration while 
watching the spot under a dissecting microscope until the solution 
turned cloudy. 
1) 2-methyl-2,4-pentane diol (MPD, 100%): clear at 40% MPD, cloudy 
at 50%; oily precipitate. 
2) Polyethylene glycol 600 (PEG 600, 40%): slightly cloudy at 8%, 
cloudy at 12%; precipitate lights and extinguishes. 
3) PEG 1000 ( 40%) : clear at 4 % , cloudy at 8% ; oil or precipitate? 
4) PEG 1500 (50%): clear at 5%, precipitate at 10%; precipitate does 
not light. 
5) PEG 6000 (50%): clear at 5%, cloudy at 10%; brownish precipitate 
- oil? 
6) Ethanol ( 100%) : hazy at 20%, cloudy at 30%; brownish precipitate. 
7) Arrnnonium acetate ( 5 M) : clear through 3 M. 
8) Amnonium citrate pH 9.0 (3M): clear at 0.9 M, cloudy at l.2M. 
9) Arrnnonium formate ( 5 M) : clear through 3 M. 
10) Arrmonium phosphate pH 8.5 (4 M): clear at 0.4 M, cloudy at 0.8 M; 
oily precipitate. 
11) Amnonium sulfate pH 8.5 (3.7 M): clear at 0.6 M, cloudy at 1 M; 
oily precipitate. 
12) Magnesium chloride (5 M): clear through 4 M. 
13) Magnesium sulfate (2 M): clear at 1.2 M, cloudy 1.4 M; oily 
precipitate. 
14) Sodium chloride (5 M): clear through 4 M. 
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Table Two: Headpiece Crystallization Trials 
The following is a list of all crystallization trials with the 
lac headpiece protein and their results. Trials are grouped according 
to the precipitant used, followed by crystallization technique, and 
ending with the specific conditions of each trial. All trials were 
set up using a headpiece protein stock at an initial concentration of 
6-7 mg/ml, containing 100 rnM KCl, 10 rnM Na cacodylate pH 7. 5, 0 .1 mM 
ethylenediamine tetraacetic acid, 0.1 rnM dithiothreitol, 0.1 rnM 
phenylmethane sulfonyl fluoride, and 0.02 % Na azide (HP buffer). 
Crystallizations in spot plates were prepared by adding concentrated 
solutions of precipitants and counterions to 10 microliter samples of 
the headpiece protein in HP buffer to give the initial starting levels 
of each component in each well. Those in hanging drops were prepared 
by adding 5 rnicroliters of the reservoir solution to 5 rnicroliters of 
the protein stock in HP buff er and suspending this over the reservior 
on a siliconized covers lip. Those in rnicrodialysis tubes were 
prepared simply by adding 10 rnicroliters of the protein stock to the 
tube and allowing the reservoir solution to diffuse in through the 
membrane, except for setups with PEG, where a low level of the 
precipitant was added directly to the tube as well. 
I. 2-methyl-2,4-pentanediol (MPD) 
A. Microdialysis; 20 % to 70 % in steps of 10 % every three days. 
1) 100 rnM armnonium phosphate pH 5.1 
Oil droplets on rnerrbrane at 20 % ; precipitate at 60 % 
that may light. 
2) 100 rnM amnonium phosphate pH 7.2 
Amorphous precipitate on rnembrane at 60 % that may be 
protein. 
3) 100 rnM amnonium phosphate pH 9.1 
Amorphous precipitate on irembrane at 70 % that may be 
protein. 
B. Vapor diffusion (spot plates); 20 % to 100 % in steps of 10 % 
every seven days. 
1) 0.85 HP buffer plus 50 mM Na cacodylate pH 7.5 
Dozens of specs by 40 % that light and extinguish. 
Precipitate ring around spot at 50 % • Spot started to 
precipitate at 70 %, was completely precipitated by 
90 % with a brownish precipitate that did not light 
(oil?). 
2) 0.85 HP buff er plus 0.4 M NaCl, 50 rnM Na cacodylate 
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pH 7.5 
Some specs floating on surf ace at 30 % that light and 
extinguish, that increased in number slightly up to 
90 %, when protein oiled out. 
3) 0.85 HP buffer plus 80 mM MgC12, 50 mM Na cacodylate pH 7.5 
Specs seen on setup. Some small, cube-like crystals 
seen at 30 % that light and extinguish poorly but 
have good shape; these were gone at 40 %. Oiled out 
at 90 %. Thousands of microcrystals in spot at 
100 %; probably salt crystals. 
4) 0.85 HP buffer plus 0.4 M MgC12 , 50 mM Na cacodylate pH 7.5 
Specs seen on setup. Some small, cube-like crystals 
seen at 30 % that light and extinguish poorly and 
have poor shape; these were gone at 40 % • Salt 
crystals at 90 % (crystal violet test). 
5) 0.85 HP buffer plus 125 mM Na2ro4 , 50 mM Na cacodylate pH 7.5 
Specs seen on setup. Salt crystal and haze in spot at 
50 %. Spot increasingly precipitated up to 100 % 
with precipitate lighting faintly. 
6) 0.85 HP buffer plus 100 mM KP04 pH 7.5 Some floating cubic forms at 30 % that light and 
extinguish poorly; gone at 40 % • Spot oiled out at 
60 %. Precipitate in spot at 100 %. 
II. Polyethylene glycol 600 (PEG 600) 
A. Microdialysis; 8 % to 36 % in steps of 4 % every three days. 
1) 100 mM amnonium phosphate pH 5.25 
Membrane appeared grainy irmnediately (oil droplets?); 
remained so up to 36 % , when two multinucleated 
crystals appeared on the glass wall. 
2) 100 mM amnonium phosphate pH 7.15 
Nothing at all seen up through 36 %. 
3) 100 mM armnonium phosphate pH 9.0 
Nothing at all seen up through 36 %. 
Ill. Annnonium sulfate 
A. Microdialysis; 1 M to 4 Min steps of 0.2 M every three days. 
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1) 10 mM Na acetate pH 5.1 
"Grainy" membrane at 1 M (oil drops?); resolved to 
hundreds of large and small oil drops on rrembrane and 
on meniscus by 1.2 M; a triangular chunk, possible 
crystal, in one drop at 2.2 M; sorre more chunks on 
membrane at 3.4 M; lots of these in oil drops at 3.6 M. 
2) 10 mM Na cacodylate pH 7.1 
"Grainy" menbrane at 1 M; hundreds of large and small 
oil drops on membrane and meniscus at 1.2 M; a few 
multinucleated crystals on membrane at 2.4 M; sorre 
fibers and possible crystals at 3.2 M that seem to 
light and extinguish; crystals or precipitate at 3.6 M; 
hundreds of microcrystals at 4 M that light and 
extinguish. 
3) 10 mM Na cacodylate pH 8.95 
A number of large (up to 0.5 rrnn across), birefringent 
clumps at 1 M that light and extinguish weakly; some 
small possible crystals and oil drops on meniscus at 
1. 6 M; oil drops with small crystals in them, and a 
huge, airorphous clump in tube at 1. 8 M; more extensive 
oiling by 2.2 M; microcrystalline-like debris at 2.4 M; 
several floating clumps at 3 M; several patches of 
material that light and extinguish radially on walls 
at 3.6 M. 
B. Microdialysis; 0.6 M to 1.8 Min steps of 0.1 M every three 
days; then 1.8 to 3.4 M in 0.4 M steps every three days; then 3.6 
to 4 M in 0.2 M steps every three days. 
1) 0 .1 nM ethylenediamine tetraacetic acid, 0 .1 rrM 
dithiothreitol, 0.1 mM Na azide pH 8.0 
A few fibrous, sheet-like crystals on the rrembrane 
that may light and extinguish at 0.6 M; a clump at 
0.8 M; a few small, nultinucleated crystals that light 
and extinguish weakly at 1.0 M; oil on the walls and 
meniscus at 1.3 M; a few dozen small, tightly-forrred 
oil drops on the rrenbrane at 1.4 M; several multiple 
layered crystals on the walls that light at 1.6 M; 
patches that light and extinguish radially on walls at 
3.4 M; several uniformly extinguishing, 0.2 rrnn crystals 
on walls at 3.8 M. 
2) 0.1 mM ethylenediamine tetraacetic acid, 0.1 mM 
dithiothreitol, 0.1 mM Na azide pH 8.5 
A few microcrystals that light at 0.6 M; one or two 
clumps that light on glass at 0.8 M; a few 
multinucleated crystals on the glass at 1 M; sorre 
tightly formed oil drops on the rrembrane and several 
poorly formed crystals on the walls at 1.2 M; light 
oiling on the walls and meniscus at 1.3 M; six to 
twelve small crystals that light and extinguish 
weakly, have poor shape at 1.4 M; several 
multinucleated crystals on the walls at 1.7 M; sorre 
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small material on the meniscus that lights at 2.2 M; 
the same but larger at 2.6 M; radially lighting patches 
on the walls and some microcrystals on the membrane at 
3.4 M; large radially lighting and extinguishing 
patches on the walls at 3.8 M. 
3) 0.1 rrM ethylenediamine tetraacetic acid, 0.1 nM 
dithiothreitol, 0.1 mM Na azide pH 9.0 
Numerous poorly formed crystals on walls and possibly 
on rrenbrane that light and may extinguish at 0.6 M; 
three or four poorly formed clumps at 0.8 M; small, 
radially lighting and extinguishing patches on the 
walls at 0.9 M; numerous microcrystals on glass and 
some floating clumps at 1 M; increasing number of these 
at 1.2 M; oil on walls, meniscus and rrembrane, along 
with some poorly formed crystals on walls at 1.3 M; 
some floating clumps that light and extinguish at 
1.4 M; numerous multinucleated crystals at 1.6 M; more 
patches on the walls, less well ordered than at lower 
pH, at 2.6 M. 
4) 0.1 mM ethylenediamine tetraacetic acid, 0.1 mM 
dithiothreitol, 0.1 mM Na azide pH 9.5 
Some clumps on the glass that do not light at 0.8 M; 
some sheet-like material on the membrane at 1.1 M; 
small oil drops on rrembrane at 1.2 M; extensive oiling 
at 1.3 M; heavy by 1.7 M; small patches on the walls at 
3.8 M. 
C. Microdialysis; 0.6 M to 3.95 Min steps of 0.2 M every three 
days 
1) SO mM aIIlllOnium phosphate pH 9. 0 
Hundreds of tiny specs that may light at 0.6 M; oil on 
irenbrane and some microcrystals on glass that light 
and extinguish rrultiply at 1 M; oil on walls and 
menbrane at 1.2 M; a large fiber that lights and 
extinguishes, and several disordered microcrystals on 
wall, along with oiling throughout tube, at 1.6 M; 
radially lighting and extinguishing patches on walls at 
3.4 M; hundreds of "starburst" crystals at 3.6 M. 
2) 250 nM ammonium phosphate pH 9.0 
Fibers and arrorphous material on walls and membrane at 
0.6 M; oil drops on membranes at 1 M; heavy oil drops 
on walls and in liquid at 1.2 M; tight oil drops and 
some microcrystals at 1.4 M; fibers and oil drops at 
2.6 M; radially lighting and extinguishing patches at 
3.4 M. 
3) SO mM MgC12 pH 9.0 Oil at menbrane at 1 M; oil throughout liquid at 1.2 M, 
heavy by 1.4 M; poorly lighting "staroorst" crystals at 
3.6 M. 
4) 250 rnM MgC12 pH 9.0 RectanguJ.ar, multinucleated crystals on membrane that 
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might light and extinguish at 0.6 M; oil throughout 
solution at 1.2 M; heavy at 1.6 M; some poor crystals 
on walls and membrane at 1.8 M. 
S) 50 mM KCl pH 9.0 
Several radially lighting and extinguishing patches on 
walls at 0.8 M; light oiling at 1.2 M; ·large, heavy oil 
drops on rreniscus at 2.2 M. 
6) 250 rnM KCl pH 9.0 
Microcrystals on membrane at 0.6 M; oil droplets on 
rrembrane at 1 M; oil throughout solution at 1.2 M; 
heavy at 1.4 M; disordered blobs at 3.8 M. 
D. Vapor diffusion (spot plates); 1.2 M to 2.S Mat 0.2S M every 
seven days, then 2.S M to 4 M at O.S M every seven days. 
1) SO rnM Na cacodylate pH 7.S 
A few particles that light and extinguish in sections 
at 1.25 M; some debris that does not light at 1.7S M; 
precipitate ring around spot at 2 M; lightly oiling in 
solution at 2.5 M; microcrystals at 3 M; some radially 
lighting and extinguishing patches at edge at 3.5 M; 
many at 4 M. 
2) 0.4 M NaCl and SO mM Na cacodylate pH 7.S 
A few floating microcrystals that light and extinguish 
at 1.5 M; a small, single crystal (?) at 2.5 M; 
precipitate ring around spot and oiling on meniscus at 
3.S M; extensive oiling at 4 M. 
3) 1 M NaCl and SO rnM Na cacodylate pH 7.S 
A few floating microcrystals at 1.5 M; some blobs that 
light with a cross pattern at 2 M; precipitate ring 
around spot and light oiling in solution at 3.S M. 
4) 80 mM MgC12 and SO mM Na cacodylate pH 7.S A few microcrystals that light and extinguish at 
1.25 M; a small (0.05 by O.lS rmn) rectangle that 
lights and extinguishes in a wave at 1.7S M; 
precipitate ring around spot at 2.25 M; oiling out at 
3 M. 
S) 0.4 M MgCl and SO mM Na cacodylate pH 7 .5 
A large fiber that lights and extinguishes at 1.25 M; 
microcrystals at 1.75 M; sore blobs that light with a 
cross pattern at 2 M; light oiling, and a small single 
crystal growing off of the fiber at 3 M; precipitate 
ring around spot at 3.5 M. 
6) l(X) mM KP04 pH 7.S Microcrystals at 1.2S M; precipitate ring around spot 
at 2 M; oiling in solution at 2.25 M; heavily twinned 
microcrystals around edge and in some of the oil drops 
at 3.5 M. 
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N. Armnonium phosphate 
A. Vapor diffusion (hanging drop); 4 M armnonium phosphate in 
reservoir. 
1) Ammonium phosphate pH 5.0 
Fiber with several small crystals growing from it, 
oiling out at one week; radially lighting and 
extinguishing patches at three weeks. 
2) Arrnnonium phosphate pH 5.5 
Oil drops at one week; small crystal at two weeks. 
3) Arrnnonium phosphate pH 6. 0 
Oiling at one week; fibers at three weeks. 
4) Arrnnonium phosphate pH 6. 5 
Oil drops at one week; microcrystals at two weeks. 
5) Arrnnonium phosphate pH 7. 0 
Oil drops and a few small microcrystals which light and 
extinguish at one week; fibers at two weeks. 
6) Ammonium phosphate pH 7.5 
Oiled out immediately on mixing. 
7) Ammonium phosphate pH 8.0 
Oiling i11llllediately on mixing; fibers at three weeks. 
8) Arrnnonium phosphate pH 8. 5 
Oiling irrnnediately on addition; possible small crystal 
at two weeks. 
9) Ammonium phosphate pH 9.0 
A couple of small crystals, one single, one multiply 
nucleated at one week. 
B. Vapor diffusion (spot plates); 1.25 M to 2.5 M at 0.25 M every 
week; 2.5 M to 4.0 M at 0.5 M every week. 
1) 1 M AIIl!lOnium phosphate pH 7.5 
A floating clump that lights and extinguishes in 
sections at 1.25 M; a "snowooll" at 1. 75 M; precipitate 
ring around spot at 2.25 M; scum (oiling out or 
precipitate?) at 3 M. 
2) 0.92 M Ammonium phosphate and 0.4 M NaCl pH 7.5 
Several clumps, sorre of which light, at 1.25 M; fibers 
and a multinucleated crystal at 2.5 M. 
3) 1 M NaCl and 0.9 M arrnnonium phosphate pH 7.5 
A salt crystal at 1.25 M. 
4) 0.94 M arrnnonium phosphate and 0.125 M Na2s::>4 pH 7.5 Spot clouded on setup; clear after one week with sorre 
debris; oiling at 2.25 M; precipitate ring around spot 
at 2.5 M; completely oiled out at 4 M. 
V. Arrnnonium citrate 
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A. Vapor diffusion (spot plates); 1 M to 3 M at 0.25 M every 
seven days. 
1) 50 rnM Na cacodylate pH 7.5 
Some fibers at 1.25 M; precipitate ring around spot and 
some microcrystals that light and extinguish at 1.75 
M; radially lighting and extinguishing patches at 2.25 
M; larger microcrystals and a faintly birefringent skin 
over bottom and surface of spot at 2.5 M; fibers along 
surface of spot at 2. 75 M. 
2) 0.43 M NaCl and 50 rnM Na cacodylate pH 7.5 
Some fibers at 1 M; microcrystals at 1.75 M. 
3) 1.1 M NaCl and 40 rnM Na cacodylate pH 7.5 
Some fibers at 1 M; more at 1.75 M; bottom oiled out at 
2.5 M. 
4) 87 mM MgCl and 47 rnM Na cacodylate pH 7.5 
A few fi~rs at 1.25 M; some microcrystals at 1.5 M; 
precipitate ring around spot at 1.75 M; oil at 2.25 M; 
around six large rosettes (approximately 2 nnn across) 
on bottom at 2.5 M; birefringent patches on surface and 
some 0.1 mm needle crystals on bottom at 2.75 M. 
5) 0.43 M MgC12 and 47 mM Na cacodylate pH 7.5 Fibers at 1.25 M; some microcrystals at 1.75 M; lots of 
fibers plus some small specs that light and extinguish 
at 3 M. 
6) 140 rnM Na2s:>li. and 48 rnM Na cacodylate pH 7.5 Fibers at I.25 M; precipitate ring around spot at 2 M; 
h.Indreds of microcrystals plus needle crystals running 
along surface that light and extinguish at 2.25 M. 
7) 100 rnM KPO pH 7.5 
Fibers a~ 1.25 M; precipitate ring around spot at 
1.75 M; microcrystals on bottom that light and 
extinguish at 2.25 M; birefringent skin on surface at 
2.5 M; a small fiber crystal (0.05 by 0.05 mm) that 
lights and extinguishes evenly at 3 M. 
B. Microdialysis; 1.5 M to 3 M in 0.25 M steps every three days 
1) pH 5.0 
Some material on nerrbrane at 1. 5 M; oiling and multiple 
sheet-like crystals at 2 M. 
2) pH 6.0 
Hundreds of possible twinned fiber crystals on membrane 
at 1.5 M; some oiling and small crystals on surface of 
rnenbrane (tube had dried out) at 2 M. 
3) pH 7.0 
Hundreds of oil drops on nerril::>rane at 1.5 M; oiling on 
surf ace at 2 M; precipitate ring around tube and 
crystalline precipitate in tube at 2.5 M. 
4) pH 8.0 
Oil drops at 1.5 M; precipitate around meniscus, 
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radially lighting and extinguishing patches on walls 
and scummy precipitate on membrane at 2.25 M. 
5) pH 9 .O 
Oiling at 1.5 M; crystalline precipitate around 
meniscus at 2.25 M; precipitate on membrane at 2.5 M. 
C. Vapor diffusion (spot plates); 2 M to 3 M armnonium citrate pH 
7.5 in steps of 0.25 M every seven days. 
1) pH 7.5 
Half-dozen blobs that light with a cross at 2 M; 
precipitate ring around spot, skin on meniscus and 
numerous small (up to 0.2 nun) rosettes in oily ring 
around spot that light and extinguish radially at 
2.25 M. 
2) 37 mM MgCl pH 7.5 
Some blo~s that light with a cross at 2 M; precipitate 
ring around spot, skin on meniscus and some small 
rosettes at 2.25 M. 
3) 209 mM MgC12 pH 7.5 Some microcrystals, some oblong crystals that light but 
do not extinguish and a thread at 2 M; a crystalline 
"half-ring" at 2.5 M; salt crystals at 2. 75 M. 
4) 43 mM Na~SJ4 pH 7.5 Blobs Ehat light with a cross at 2 M; skin on 
meniscus, precipitate ring around spot and rosettes 
around edge at 2.25 M; several large patches that 
barely light but extinguish at 2. 75 M. 
5) 209 mM Na2s:::>4 pH 7.5 Microcrystals, a film on the surface of the spot with 
thread-like fibers running along it and a slight 
precipitate ring around spot at 2 M; rosettes at 2.25 
M. 
6) 43 mM KP04 pH 7.5 Some thread-like crystals and microcrystals at 2 M; a 
skin with a thready birefringence on the surface of and 
a precipitate ring around the spot at 2.25 M; 
"snowballs" at 2.5 M. 
7) 209 mM KPO pH 7.5 
Some mic~ocrystals and crystalline aggregates that 
light at 2 M; skin on surface with "snowballs" around 
edge at 2.5 M. 
D. Vapor diffusion (spot plates); 2 M to 3 M armnonium citrate pH 
8.5 in steps of 0.25 M every seven days. 
1) pH 8.5 
Crystalline ring around spot and birefringent skin on 
spot at 2 M; "snowballs" at 3 M. 
2) 50 mM MgC12 pH 8.5 
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Some blobs that light with a cross at 2 M; skin on 
surface and a crystalline ring of 0.15 mm long fibers 
around spot at 2.25 M. 
3) 250 mM MgCl pH 8.5 
A few blots that light with a cross at 2 M; a ring of 
microcrystals around edge of spot at 2.25 M; skin over 
surface at 2.5 M; crystalline patches on skin at 
2.75 M; salt crystals at 3M. 
4) SO mM Na2S\ pH 8.5 Skin on surf ace and crystalline ring around spot at 2 
M. 
5) 250 mM Na2s:>u pH 8.5 Ring of fiber crystals around spot and nonbiref ringent 
skin on surface at 2 M; crystals growing larger with 
increasing salt concentration; a chunk that lights and 
extinguishes weakly at 2. 75 M. 
6) 50 mM KPO pH 8.5 
Nonbiref ringent skin on surf ace and crystalline fiber 
ring around spot at 2 M; a chunk that lights weakly at 
2.5 M. 
7) 250 mM KP04 pH 8.5 Precipitate ring around spot and nonbiref ringent skin 
on surface at 2 M; did not change. 
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Table Three: Headpiece/Operator Crystallization Trials 
The following is a list of all cocrystallization trials with the 
lac headpiece protein and the 21 base-pair lac operator DNA oligomer 
and their results. Trials are grouped according to precipitant used, 
followed by crystallization technique, and ending with the specific 
conditions of each trial. All trials were set up using a headpiece 
protein stock at an initial concentration of 6-7 ng/ml, containing 100 
rrM KCl, 10 mM Na cacodylate pH 7 .5, 0.1 mM ethylenediamine tetraacetic 
acid, 0 .1 mM dithiothreitol, 0 .1 nM phenylmethane sulf onyl fluoride, 
and 0.02 % Na azide (HP buffer); operator stock was at a 
concentration of 12 ng/ml in water. Crystallizations in spot plates 
were prepared by adding concentrated solutions of precipitants and 
counterions to 5 microliter samples of the operator DNA with various 
amounts of the protein to give the initial starting levels of each 
component in each well. NOTE: In this chart a 1:1 ratio of headpiece 
protein to operator rreans two protein molecules per DNA strand, since 
the operator has two headpiece binding sites in it. 
I. Polyethylene glycol (PEG) 6000 
A. Vapor diffusion (spot plates): 10% to 30%, at 5% per week. 
1) 1:1 headpiece:operator 
A large (0.1 x 0.25 nun) twinned crystal that lights 
and extinguishes rrultiply, plus a slight ring and specs 
at 10%; the ring gone but the rest the sane at 15%. 
2) 2:1 headpiece:operator 
Some specs and a slight ring at 10%; oiling out on 
surface, plus thousands of small (<0.05 nun) shapes 
that light with a cross pattern at 25%. 
3) 1:1 headpiece:operator plus 10 mM MgCl 
Some specs and a ring at 10%; hundreas of oil drops of 
all sizes (up to 0.1 nun) that light with a cross on 
surf ace and bottom of spot at 25%. 
4) 2:1 headpiece:operator plus 10 mM MgC12 Some specs and a ring at 10%; oil drops and numerous 
shapes that light with a cross at 15%; larger (up to 
0.15 nnn across) at 25%. 
5) 1:1 headpiece:operator plus 100 mM MgC12 Some specs and a ring at 10%; numerous shapes on 
surface and bottom that light with a cross at 15%. 
6) 2:1 headpiece:operator plus 100 mM MgCl 
Some specs and a slight ring at 10%; ~apes that 
light with a cross and a few floating crystals that 
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light and extinguish at 15%. 
II. 2-methyl-2,4-pentanediol (MPD) 
A. Vapor diffusion (spot plates): 20% to 80%, at 10% per week. 
1) 1:1 headpiece:operator 
Shapes that light with a cross at 20%; sorre multiple 
crystals at 40%; hundreds of long, thin crystals that 
light and extinguish singly, none greater than 0.05 nnn 
long, on surface and bottom at 60%; some square 
crystals that appear deep red under polarizer at 70%. 
2) 2:1 headpiece:operator 
Shapes that light with a cross at 20%; slight ring 
around spot at 50%; hundreds of tiny rectangular 
crystals that light and extinguish singly at 60%; 
salt crystal at 70%. 
3) 1:1 headpiece:operator plus 10 mM MgCl 
Some fibers and specs at 20%; some s~apes and a few 
small, ill-formed crystals (the largest 0.025 x 0.1 nnn) 
that light and extinguish singly at 40%; hundreds of 
twinned crystals, each two rectangular crystals joined 
end-to-end at a slight angle, most having poor form, 
but some being well-formed and lighting and 
extinguishing singly, at 50%; spot slightly 
precipitated at 60%; less precipitated at 70%. 
4) 2:1 headpiece:operator plus 10 mM MgC12 Some specs at 20%; hundreds of well-ordered but 
smaller twinned crystals at 50%; larger, sorre up to 
0.1 nnn long, also spot slightly precipitated at 60%; 
fewer crystals at 70%. 
5) 1:1 headpiece:operator plus 100 mM MgC12 Some specs at 20%; thousands of shapes that light 
with a cross at 50%; hundreds of small (<0.05 nnn on 
edge), cube-like crystals that are well-formed, not 
twinned, light and extinguish singly and appear deep 
red under the polarizer, plus some precipitate at 60%. 
6) 2:1 headpiece:operator plus 100 mM MgC12 Some specs at 20%; thousands of shapes that light 
with a cross at 50%; thousands of specs at 60%; 
smaller crystals plus amorphous blobs and twinned 
clusters of crystals at 70%. 
B. Vapor diffusion (spot plates): 20% to 60%, at 10% per week. 
1) 1:1 headpiece operator plus 10 mM CaC12 Some specs at 20%; a few shapes that light with a 
-74-
cross at 30%; hundreds of multinucleated crystals, 
plus a few twinned crystals, measuring up to 0.05 x 
0.2 nnn that light and extinguish beautifully as two 
crystals joined end-on-end, at 40%; clusters of 
rrultinucleated crystals and only a few tiny single 
crystals at 50%. 
2) 2:1 headpiece:operator plus 10 rnM CaC12 Some specs at 20%; some fibers and specs and a slight 
ring at 40%; thousands of powderlike crystals on the 
surface and bottom that light and extinguish at 50%. 
3) 1:1 headpiece:operator plus 10 rnM Sr(JIU3)2 Some specs at 20%; faint ring around spot at 30%; 
thousands of end-on-end twinned crystals, none larger 
than 0.05-0.1 nnn at best and not well-formed but which 
light and extinguish at 40%; hundreds of small 
rectangular crystals that light and extinguish on 
surface and on bottom of spot at 50%. 
4) 2:1 headpiece:operator plus 10 rnM Sr(N03)2 Some specs at 20%; faint ring around spot at 30%; 
numerous end-on-end twinned crystals that are smaller 
than in 3) but better formed and have a reddish 
streak in them under polarizer at 40%. 
5) 1:1 headpiece:operator plus 10 mM BaC12 Some specs at 20%; ring around spot at 30%; thousands 
of very small end-on-end twinned crystals that light 
and extinguish at 40%; thousands of needles on surface 
and bottom at 50%. 
6) 2:1 headpiece:operator plus 10 rnM BaC12 Some spheres that light with a cross at 20%; a ring 
around spot at 30%; thousands of fibrous, needle 
crystals that light and extinguish at 40%; slightly 
larger needles at 50% 
C. Vapor diffusion (spot plates): 20% to 60%, at 10% per week 
1) 1:1 headpiece:operator plus 7.55 rnM MgCl 
Some spheres that light with a cross at 20%; a ring 
around spot at 40%; tiny needle crystals, single, 
rrultiple and in clusters at 50%. 
2) 0.5:1 headpiece:operator plus 12.78 rnM MgC12 Some specs at 20%; hundreds of "snowball" crystals 
plus some end-on-end twinned crystals and cubic 
crystals that light and extinguish, all <0.05 nnn, at 
40%; hundreds of cubic crystals on surface that light 
and extinguish as rrultiple crystals at 50%. 
3) 1.5:1 headpiece:operator plus 10 mM MgC12 Some specs at 20%; a ring around spot at 40%; 
hundreds of tiny needles at 50%. 
4) 2:1 headpiece:operator plus 10 rnM MgC12 Some specs at 20%; dozens of end-on-end twinned 
crystals, not very good shape but up to 0.05 x 0.3 mm 
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that light and extinguish at 407.. 
5) 2:1 headpiece:operator plus 20 mM MgCl 
Some specs at 207.; "snowball" crystats, plus some 
small end-on-end twinned crystals at 407.; the latter 
larger (up to 0.2 nnn) but not well-ordered at 507.. 
D. Vapor diffusion (spot plates): 207. to 607., at 107. per week 
1) 2:1 headpiece:operator plus 20 mM MgCl 
Some specs at 207.; numerous specs, ptus some small 
(0.5 rrnn on edge) cures that light and extinguish at 
307.; scores of end-on-end twinned crystals (up to 0.05 
x 0.15 rrnn), with reasonable shape and that light and 
extinguish, at 407.. 
2) 2:1 headpiece:operator plus 1 mM spermine"HCl pH 7.0, 20 
mM MgC12 Some specs at 207.; thousands of spheres that light 
with a cross around edge of spot at 307.; thousands of 
tiny microcrystals on surf ace and on bottom of spots at 
407.. 
3) 2:1 headpiece:operator plus 3 mM spermine"HCl pH 7.0, 66 
mM MgCl 
Sp§t precipitated on addition of spermine and did not 
resuspend until 66 mM Mg added; some specs at 207.; 
hundreds of tiny crystals on surf ace plus dozens of 
large spiral crystals on bottom that light and 
extinguish at 407.. 
4) 2:1 headpiece:operator plus 40 mM MgC12 Some specs at 207.; hundreds of cubic crystals and 
end-on-end twinned crystals on surf ace and bottom that 
have good shape and light and extinguish, but are too 
small, at 407.; small crystals and rosettes at 507.. 
5) 1:1 headpiece:CGCGAATICGCG (plus 1 spermine, 25 MgC12) Some specs at 207.; half a dozen large (up to 0.15 x 
0.8 rrnn ) native DNA crystals (no changes in OKL from 
native pattern) at 407.. 
6) 2:1 headpiece:CGCGMITCGCG (plus 1 spermine, 25 MgCl ) 
Some specs at 207.; some poorly formed crystals at ~07.. 
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Figures 
Figure 1. Sephadex G-50 Fine colunm. Fractions 41-52 represent 
excluded volume; fractions 71-86 the headpiece fraction; 
fractions 105-115 the fully included volume. 
Figure 2. SDS polyacrylamide gel showing the course of the headpiece 
rorification. Gel is a 5 to 20% linear gradient gel containing 7M 
urea, according to the protocol of Horigome et al. (Horigome, T. , 
Yoshida, K., Kanai, Y. and Sugano, H (1980) Seibutsu Butsuri Kagaku 
24, 187-190). 
Lane 1: repressor protein before proteolysis. 
Lane 2: repressor after 3 hours of proteolytic digestion at 20°c 
with alpha-chymotrypsin (1 mg enzyme per 100 mg repressor). 
Lane 3: digest after first lima bean trypsin inhibitor colunm. 
Lane 4: load-wash of first P-11 column. 
Lane 5: high-salt elution peak of first P-11 colunm. 
Lane 6: First peak (fractions 41-52) of Sephadex G-50 Fine colunm. 
Lane 7: Second peak (fractions 71-86) of G-50 colunm. 
Lare 8: second P-11 column high-salt elution peak. 
Lane 9: final, concentrated headpiece (approx. 6 mg/ml). 
Lane 10: headpiece final product after a 14 day incubation at 4°C in 
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Introduction 
The final chapter describes our structural study of the B-DNA 
12mer C-G-C-G-A-A-T-T-C-G-C--G complexed with the DNA fluorochrome 
Hoechst 33258. Hoechst is a member of a large and very important 
class of DNA binding molecules that are characterized by their ability 
to bind to B-form DNA in the minor groove. As reviewed recently by 
Zinnner and Waehnert ( 5), this group includes a number of important 
antibiotic and antitumor agents, such as distamycin A, netropsin and a 
host of others, which all share a connnon set of characteristics. 
First of all, each one interacts with DNA in a nonintercalative manner 
by binding in the minor groove. Characteristically, rather than 
disrupt the structure of the DNA, they instead strengthen the double 
helix, often leading to such effects as an increase in melting 
temperature and greater stability of the B conformation. Also, they 
tend to be sequence-preferring rather than sequence-specific, for 
example, having a high affinity for AT-rich over GG-rich regions or 
vice versa. Another characteristic is a dual mode of binding, with 
many of the compourrls exhibiting a more specific, tight-binding mode 
to certain sequences along with a less specific, weaker binding to DNA 
in general. Work by Denny et al. (1) has shown that the nature of 
this tight-binding interaction may be correlated to antitumor activity 
in at least some of these compounds, suggesting that proper design of 
such molecules may lead to drugs with high activity against a number 
of diseases. 
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Our interest in these mi.nor groove binders began with our 
analysis of a complex of the antitumor compound netropsin with 
C-G-C-G-A-A-T-T-BrC-G-C-G (3, 4). The structure revealed how this 
AT-specific binder fit into the mi.nor groove of the AT center of the 
12mer, steered into place by a series of bifurcated hydrogen bonds 
between the drug and groups on the base-pair edges of the groove. In 
the process, it replaces a series of ordered waters in the groove of 
the DNA thought to help stabilize it, which we call the "spine of 
hydration," forming an even stiffer spine and thereby accounting for 
the dramatic rise in melting temperature seen on netropsin binding to 
double-helical B DNA (2). In addition, the reason for the molecule's 
strong preference for AT-rich regions was shovm to be due to a series 
of close steric contacts between the drug and the bottom of the 
groove, contacts that would not be allowed in GC-rich regions due to 
the presence of the guanine N2 amine group. This latter observation 
led to the suggestion of a new series of molecules that could exploit 
this van der Waals contact to preferentially steer them to either GC-
or AT-rich regions, which we refer to as "lexitropsins." 
We became interested in Hoechst because both its structural 
features and its known high affinity for AT-rich regions of DNA 
suggested to us that it might be another mi.nor groove-binding compound 
like netropsin. Possessing anthelnti.ntic properties as well as being a 
widely used DNA fluorochrome, it was intriguing because it not only 
would bind to AT-rich regions but also had a tolerance for GC-rich 
regions as well, making it an example of both types of binding in one 
molecule. The structure confirmed our predictions for mi.nor groove 
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binding, reinforcing our rocx:lel for the way in which AT-specific 
binding compounds work. It also provided an example of a Ge-specific 
binding interaction with the groove and unexpectedly revealed how 
conformational variation in the molecule can influence sequence 
preference. The detailed structure analysis of Hoechst 33258 is given 
in the following paper. 
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Surmnary 
An x-ray crystal structure analysis has been carried out of the 
complex between the antibiotic and DNA fluorochrome Hoechst 33258 and 
a synthetic B-DNA dodecamer of sequence: C-G-C--G-A-A-T-T-C-G-C-G. 
The drug molecule, which can be schematized as: 
phenol-benzimidazole-benzimidazole- piperazine, sits within the minor 
groove in the A-A-T-T region of the DNA double helix, displacing the 
spine of hydration that is found in drug-free DNA. The N-H of 
benzimidazoles form bridging three-center hydrogen bonds between 
adenine N3 and thymine 02 atoms on edges of base pairs, in a manner 
both mimicking the spine of hydration and calling to mind the binding 
of the antitunor drug netropsin. Two conformers of Hoechst are seen 
in roughly equal pop..ilation, related by 180° rotation about the 
central benzimidazole-benzimidazole bond: one form in which the 
piperazine ring extends out from the surf ace of the double helix, and 
another in which it is buried deep within the minor groove. Steric 
clash between drug and DNA dictates that the 
phenol-benzimidazole-benzimidazole portion of Hoechst 33258 binds only 
to Kr regions of DNA, whereas the piperazine ring demands the wider 
groove characteristic of GC regions. 
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1. Introduction 
Hex:?chst 33258 (Figure la) is a member of a large class of 
compounds whose useful and interesting properties derive from their 
ability to bind to nucleic acids. A synthetic preparation of the 
Hoechst Pharmecutical company, it was originally developed as one of a 
series of N-methylpiperazine derivatives of potential clinical use 
(36). It showed no antineoplastic activity, but was found to be 
fairly effective as an anthelmintic (~, 31). Its major usefulness, 
however, comes from its ability to fluoresce specifically when bound 
to DNA. It has been used widely as a cytological stain, both in vitro 
and in vivo, forming a brightly fluorescent complex with chromosomes, ---
with a marked specificity for AT-rich regions (12, 13, 28). In DNA in 
which thymidine has been substituted by bromodeoxyuridine (BrdU), the 
fluorescence of Hex:?chst 33258 is quenched, and this effect has been 
used as a sensitive probe for DNA replication and strand exchange in 
dividing cells (17, 33, 46). Growth of cells on low levels of Hex:?chst 
results in a number of effects on replicating chromosomes, including 
decondensation in AT-rich regions (14, 40), the induction of breaks in 
"fragile" sites ( 44), stage-specific inhibition of cell growth ( 15), 
the induction of polyploidy and endoreplication in cell lines (29), 
and, in conjunction with BrdU, an increased sensitivity to lN killing 
in growing cells ( 49, 51, 52). Other uses have included 
fluorescence-activated sorting of chromosomes (27); a method of 
separating DNA based on AT content due to induced changes in 
electrophoretic mobility (38, 44); and as a diagnostic test for 
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mycoplasma contamination in marmnalian cell lines (2). 
How Hoechst works is determined by the nature of its interaction 
with DNA, and physiochemical studies of this interaction both with DNA 
in solution and in the cellular milieu have revealed the following 
picture. Hoechst exhibits two modes of binding to nucleic acids: a 
low-level, tight-binding mode and a high-level, low-affinity mode, 
which have quite different characteristics (1, 53). The former mode 
occurs at a drug-to-phosphate ratio of less than 0.05-0.20 (42), with 
a tight-binding constant of approximately 106-107 M-l (43), is 
unaffected by 0.01 to 1.0 M salt, is proportional to the percent AT 
base-pairs in the duplex (35), is noncooperative, and leads to 
induction of fluorescence which is also proportional to percent Kr 
(34). The latter mode begins to predominate at a drug-to-phosphate 
ratio of greater than 0.1, has a weaker binding constant of 104-105 
M-1, is abolished at high salt, is insensitive to the base composition 
of the polymer, is highly cooperative, and causes quenching of the 
fluorescence generated by specific binding. Because its physical 
characteristics are those that desribe the behavior of Hoechst as a 
f luorochrome and a drug, the tight-binding mode is the one of 
biochemical and pharmaceutical interest and the one that we have 
studied. 
This tight-binding interaction seems to represent binding to 
double-stranded DNA in the B form, since binding to single-stranded 
forms ( 48) , to RNA-RNA or RNA-DNA duplexes ( 43), or to DNA under 
conditions in which it assumes the A form (42), is seen to be of the 
low-affinity type. Binding causes characteristic shifts in the drug's 
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absorption maxinum from 338 to 345-356 nm, the induction of circular 
dichroism at 355 nm, and of fluorescence emission at 505 nm, all of 
which are observed to be proportional to the percent AT of the nucleic 
acid under high salt conditions (3, 35, 56). The binding does not 
appreciably disrupt the DNA structure, as seen by the small changes in 
its electric dichroism and birefringence properties ( 1) • The main 
effect is a dramatic rise in T , increasing by 4° C in poly (CG) and 
m 
40° C in poly (AT), with this increase in mixed polyrrers being 
proportional to percent AT ( 3). Competition with other compounds 
known to bind to DNA by various intercalative and nonintercalative 
modes of bonding show effects on Hoechst binding only in the case of 
minor groove, AT-specific binders (32, 50), although GC bases lying 
within AT stretches are tolerated by the dye (16). The minor groove 
is also implicated as the specific site of binding because poly (IC) 
is more similar to poly (AT) than to poly (CG) in binding properties, 
and because Hoechst binds well to phage T6 DNA, in which the major 
groove is blocked by glycosylation (42). When bound, the dye is shown 
to lie at a 45 to 49° angle to the helix axis, consistent with minor 
groove binding (20, 39). Sensitivity of binding to the presence of 
guanidine·Hcl but not to NaCl or urea suggests a combination of 
hydrogen bonding and electrostatic components to binding, and 
titration curves of the dye with DNA of various base compositions 
indicate that three hydrogen bonding sites are involved (42, 53). 
Several f ootprinting studies indicate that the Hoechst binding site 
spans three to five bases (11, 41). Based on this evidence, a model 
has been proposed in which the dye binds nonintercalatively in the 
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minor groove, with the N groups of the two benzimidazole rings and the 
N-methyl group of the piperazine ring making three hydrogen bonding 
interactions with the N3 and 02 groups of AT base pairs in the bottom 
of the groove ( 11, 42). 
We became interested in Hoechst because these properties made it 
a member of an important class of DNA-binding drugs, such as 
distamycin and netropsin, which bind to DNA in the minor groove. We 
had previously studied a complex of the AT-specific binding netropsin 
(Figure lb) with a twelve base-pair DNA oligorner of sequence 
C-G-C-G-A-A-T-T-BrC-G-C-G by single crystal x-ray diffraction analysis 
(25, 26). Our results showed that this drug indeed binds to the 
B-f orm dodecarner by fitting into the minor groove of the central 
A-A-T-T region. In doing so, it displaces a series of ordered water 
trolecules seen in the native DNA structure, termed the "spine of 
hydration," which help to stabilize the B conformation. Netropsin 
mimics this spine by forming a series of bifurcated hydrogen bonds 
with the base edges in the groove, explaining both its binding 
preference for KT sequences and its stabilizing effect on B-DNA. 
Hoechst's physical and physiochemical similarities to netropsin 
prompted us to carry out a similar analysis to a resolution of 2.2 
Angstrom. Our results show that the same mode of minor groove binding 
occurs in Hoechst as in netropsin, confirming and expanding the 
conclusions of previous studies. In addition, Hoechst exhibits an 
unexpected conformational duality in binding, which explains its 
ability to tolerate GC base-pairs. These results have important 
implications for understanding the compound's properties as a DNA 
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fluorochrome and drug, and valuable lessons for the understanding and 
design of molecules that bind to DNA. 
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2. Results : Drug Binding Within the Minor Groove 
The crystal structure of the complex of Hoechst 33258 with a 
double-helical B-DNA oligomer of sequence: C-G-C-G-A-A-T-T-C-G-C-G 
was solved as outlined under Experirrental Procedures. Plate IA and 
Figure 2 show how the Hoechst melecule sits within the minor groove, 
and how it displaces an ordered zig-zag string of water molecules, or 
spire of hydration, that is present in the free DNA (7, 23). This 
spine of hydration has two layers: A first hydration shell of water 
molecules forms hydrogen-bonded ridges between adenine N3 and/or 
thymine 02 atoms on opposite helix strands and on adjacent base pairs 
~ between the bases in these pairs that are brought closer together 
by helix rotation. A second shell of waters then bridges the 
first-shell molecules, giving them an approximate local tetrahedral 
coordination. The spine is well-developed in the A-A-T-T center of 
the DNA helix, but breaks up as it enters the C-G-C-G regions above 
and below, mainly because of steric hindrance from guanine C2 amine 
groups. This spine of hydration is believed to make an important 
contribution to the stabilization of B-DNA, relative both to 
interconversion to another helix type, and to unwinding into singe 
strands. 
The Hoechst 33258 molecule displaces the spine of hydration in 
the region where the drug binds (Figure 2b). But its nitrogen atoms 
on the concave side of the molecule form bifurcated or tw04:enter 
hydrogen bonds (19, 54) that bridge exactly the same pairs of DNA 
atoms as did the spine of hydration. The hydrogen-bonded backbone of 
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the spine is replaced by a covalently bonded drug backbone, conferring 
added stability on the B-DNA double helix. This behavior of Hoechst 
is very much like that of netropsin (25, 26). 
Actual distances between potentially hydrogen-bonding N and 0 
atoms of DNA and drug or water are given in Figure 3. In the center 
of the spine of hydration in free DNA, the N--0 and N-N distances are 
reasonable for conventional hydrogen bonds, ca. 2.80 Angstrom. As the 
spine enters the c·c b3.se pair regions above and below, it pulls away 
from the floor of the minor groove, making the N-0 and N-N distances 
considerably longer. Ultimately, the spine of hydration in the 
dodecarner crystals ends when its way is blocked by 3'-0H groups from 
the ends of overlapping neighboring roc>lecules. 
In the Hoechst complex, the two benzimidazole nitrogens, Nl and 
N3, sit at somewhat long but reasonable distances from DNA 02 and N3 
atoms, but the piperazine ring is less comfortably fitted into the 
groove. Because of the geometry of its attachrrent to the first 
benzimidazole, the phenol group projects up at an angle to the bottom 
of the minor groove, and its -OH is not in a favorable position for 
direct hydrogen lxmding to base edges. In fact, as Figures 2b and 3b 
indicate, the phenol -OH functions as a second-shell hydrating atom, 
with a bond to water no. 71 and from there to the DNA 02 and N3 atoms. 
A somewhat disordered half of the original spine of hydration 
continues up the minor groove in the region not occupied by the drug. 
The two aromatic benzirnidazole rings of Hoechst, like the pyrrole 
rings of netropsin, are slotted tightly into the narrow A.T region of 
a minor groove that is barely wide enough to admit them. The 
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tightness of fit can be appreciated from the cross section through the 
first benzimidazole (Bzl) in Plate ID, showing van der Waals' 
nonbonded packing surfaces. As will be seen in the next section, this 
fit is so constricted that the DNA must adapt slightly in order to 
admit the drug molecule • In order that each benzimidazole group 
should fit parallel to the walls of the groove in its own local 
region, Bzl and Bz2 must be twisted by 36° around the bond that joins 
them. The phenol ring, in contrast, remains coplanar with Bzl and 
hence is not parallel to the walls of the groove in its innnediate 
neighborhood (Plate IC). 1his probably represents a tradeoff in 
energy between efficient packing within the groove, vs. the resonance 
stabilization that occurs if Phe and Bzl constitute one large, planar 
conjugated bond system. Such a tradeoff is permissible because Phe 
does not sit as deep down in the minor groove as do Bzl and Bz2. The 
bond between Phe and Bzl, being symmetrical about the midline of Bzl, 
does not allow the drug molecule to follow the curvature of the groove 
itself. 
The piperazine ring is involved in yet another type of 
conformational energy tradeoff. Steric clash between piperazine -CH2-
and benzimidazole -CH- makes the most stable situation for the free 
drug in solution one in which the best nean planes through Pip and Bz2 
are roughly at right angles to one another. Yet a snug fit within the 
minor groove would favor these two rings' being nearly coplanar. The 
compromise between these mutually conflicting demands is seen in cross 
section in Plate IE. The best plane through the puckered Pip ring 
lies approximately 60° away from the midplane of the minor groove. 
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The narrowness of the groove apparently forbids its turning any 
farther about the bond connecting it with Bz2. Even this compromise 
is possible only because Pip sits in a c·c region of the groove, a 
region that is intrinsically wider than the A.T region (see Figure 8 
of Reference 9). Pip thus actually favors a c·c region over an A·T, 
in contrast to the behavior of Bzl and Bz2. Moreover, the guanine 
-NH2 that would prevent Bzl and Bz2 from approaching the bottom of the 
groove closely enough to act as donors in hydrogen bonds actually aids 
in holding down Pip; the rotated, puckered ring does not sit deeply 
enough in the groove for the -NH2 to be a steric hindrance, and the 
-NH2 actually donates a long hydrogen bond to the terminal N6 atom of 
piperazine. 
There is yet one further twist to the piperazine story. The 
observed electron density during x-ray structure analysis suggested a 
statistical distribution of the piperazine ring between two alternate 
positions, shown in Plate IB and Figure 4. In the position that has 
been discussed so far, Pip rests down in the minor groove (Figure 4a), 
whereas in the alternate position it extends out of the groove (Figure 
4b). Least-squares refinement suggested a roughly equal population 
between these two states. Note that interconversion between the two 
Pip conformations is not something that can occur when Hoechst 33258 
is bound to DNA, since it requires an 180° rotation about the bond 
connecting Bzl and Bz2. Binding to DNA can only "freeze out" a 
conformation equilibrium that pre-existed in the free drug molecule in 
solution. But as will be mentioned later in the Discussion, these two 
conformers of Hoechst enable it to tolerate both A.T and B.T base 
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pairs at one end of its binding site. Hence, in this respect, the 
base specificity of Hoechst 33258 differs from that of netropsin. 
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3. Results : Effects of Drug Binding ~ DNA Structure 
As with netropsin, so the binding of Hoechst 33258 has very 
little effect on the local helix parameters of DNA. Table I compares 
mean helix parameters for these two drugs, with the respective 
variants of free DNA to which they were complexed. (Hoechst should be 
compared with native DNA, and netropsin with MPD7). Helical twist and 
rise per base pair are virtually unchanged by the binding of either 
drug, as are the inclination of base pairs to the helix axis and their 
displacement from that axis. The main alterations in helix parameters 
produced by binding of Hoechst are a 5° mean increase in propeller 
twist and a shift of main chain torsion angle delta (C5'-C4'-C3'-03') 
0 at purines by an average of 10 toward a more C2'-endo-like 
conformation. Pyrimidines remain clustered in the Cl'-exo region. 
The structural significance of these small changes is not clear, since 
equivalent small changes were observed between the two variants of the 
drug-free DNA helix: native and MPD7. 
Both Hoechst and netropsin do exert two overall effects on the 
DNA: they widen the minor groove and bend the helix axis backward by 
7-8° at the binding site. Both of these effects can be seen in Figure 
5, which is a superposition of the OOA helix alone with that when the 
OOA is complexed with Hoechst. The most marked widening of the groove 
occurs in the region of Bz2 and Pip and is produced primarily by 
movement of phosphates PlO and Pll. These shifts are shown 
quantitatively in Figure 6. The widening, as measured by nearest P-P 
distances across the groove, is +0.76 Angstrom (A) at step P9-P20 near 
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Bzl, +2.07 A at Pl0-Pl9 near Bz2, +1.70 A at Pll-Pl8 near Pip, and 
+l. 40 A at Pl2-Pl 7 beyond the end of the drug molecule. Corresponding 
groove widenings at these same four positions in the netropsin complex 
are: +o.16 A, +1.94 A, +1.54 A, and +1.16 A, respectively. 
The bending back of the helix axis produced by binding of Hoechst 
can be shown quantitatively in the base pair normal vector plot, 
Figure 7. The view in this plot is down the helix axis, and points 
1-12 are the ends of vectors that describe the change in normal vector 
orientation produced by drug binding. Points for the upper half and 
the lower half of the helix cluster around two different regions, 
whose separation on this plot indicates a bend of ca. 7° in helix 
axis. Moreover, the bend is concave away from the Bz2 binding site, 
suggesting that it is a consequence of drug binding. 
This is precisely the region of greatest minor groove-widening as 
well. Netropsin shows similar behavior: greatest widening near the 
propylamidinium end of the molecule (lower left in Figure lb), and a 
bending of s0 in the helix axis • In Hoechst, this drug-induced 
bending is superimposed on a prior natural bend of 19° in the axis of 
the drug-free DNA, a bend that is roughly at right angles to that 
produced by the drug (7). 
-98-
4. Discussion 
'Ihe observed DNA binding behavior of Hoechst 33258 is explained 
very cleanly by the structure of the complex. Hoechst, like 
netropsin, binds within the minor groove, displacing the spine of 
hydration that is present in the free DNA (Figure 8). 'Ihe covalent 
backlxme of the drug rrolecules stabilizes the B helix conformation 
even more effectively than did the hydrogen-txmded spine. 'Ihe 
DNA-drug complex is held together by a combination of specific 
bridging hydrogen txmd to base edges, electrostatic attraction between 
the cationic drug and the anionic DNA, and hydrophobic interactions 
resulting from the burying of aromatic rings deep within a narrow 
cleft. Part of this hydrophobic stabilization undoubtedly is entropic 
in origin - created by the dispersal of water molecules that formerly 
sat in regular array down the minor groove. 
Each drug makes the greatest perturbation in DNA structure at its 
lower end as drawn in Figure 8 - the piperazine ring for Hoechst and 
the propylamidinium tail for netropsin. 'Ihe groove is opened up more 
at that end of the drug than at the other. Both the phenol ring of 
Hoechst and the guanidinium of netropsin are lifted up somewhat from 
the floor of the groove and are not fitted in as tightly. But for 
both drugs, the snug fit within the groove forces the helix axis to 
bend backwards by 7° or 8° in the region of binding. 
Since the Hoechst and netropsin molecules are of similar size, it 
is not surprising that f ootprinting experiJIEnts show them to protect 
the same size binding site. Hoechst makes one fewer bridging hydrogen 
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bonds than does retropsin, which probably explains why its binding 
constant to DNA is lower by two orders of magnitude. 
'Ihe observed requirerrent of A0 T regions of DNA for binding of 
both Hoechst and netropsin (as well as a great number of other 
groove-binding drugs) arises not from anything as sophisticated as a 
hydrogen bond pattern, but from simple steric hindrance. 'Ihe C2 amine 
of a guanine would not permit the drug to fit deeply enough into the 
groove to make a stable complex. Hence, the aromatic benzimidazole 
rings of Hoechst and pyrrole rings of netropsin are A"T-reading 
structural elements. In contrast, the piperazine ring of Hoechst can 
be regarded as a weak G"C-reading elerrent . Steric hindrance about the 
bond to benzimidazole forces the piperazine ring to lie roughly 
crossways across the goove. This rreans that the ring is sufficiently 
far off the floor of the groove that a guanine C2 amine group no 
longer is an impedirrent; quite the contrary, it contributes an 
additonal hydrogen bond to the terminal nitrogen of the piperazine 
ring. Moreover, the crossways positioning of piperazine means that it 
cannot fit within the intrinsically narrower A"T regions of a B-DNA 
minor groove. It must have the added width that comes only with c·c 
regions. If such a wider groove is unavailable, then Hoechst can 
reorient about its central benzimidazole-benzimidazole bond, to yield 
an alternate conformation in which the piperazine ring extends out of 
the groove (Plate IB, Figure 4b). Piperazine evidently makes a 
relatively unimportant contribution to the binding of Hoechst, since 
even in the m::>st favorable case as observed in this crystal structure 
analysis, the external-piperazine conformation is adopted by roughly 
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half the molecules in the crystal. 
Hoechst 33258 is an interesting mixture of adaptation and 
maladaption to the geometry of B-OOA. The fluorescence behavior of 
the fused five- and six-ring benzimidazole molecule is what makes 
Hoechst useful as a chromosomal stain. The fused rings also create an 
asyrmnetric bond geometry that induces a 30° bend from one unit to the 
next in a chain built by linked benzimidazoles. This is well-suited 
for following the minor groove as it winds its way up the DNA helix; 
the analogous bend for the [pyrrole-amide] unit in netropsin is 36°. 
But this curvature in Hoechst is interrupted at the phenol; the -OH 
in the ~ position fails to curve and is held too far away from the 
floor of the groove for hydrogen bonding. In fact, as Figures 2b and 
8c show, the phenol -OH takes the place of a second shell water in the 
spine of hydration, binding instead to another water molecule that 
itself makes a normal 02-to-N3 bridge across two bases. If the phenol 
-OH were in the meta position, then the 60° bend introduced in the 
drug molecule would bring the -a-I too close to the floor of the 
groove. At the other end of the Hoechst molecule, the piperazine ring 
is functionally similar to a benzimidazole, with nonpolar sides and 
polar, hydrogen-bonding keel. But its cross section is utterly 
different: broad and shallow rather than tall and thin. Hence, it 
requires a different kind of minor groove region for binding: the 
broader groove that is associated with c·c base pairs. 
The preference of a puckered six-membered ring for c·c regions of 
DNA is also seen in other drug molecules, including some that 
intercalate between base pairs. In the complex of the antitumor drug 
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daunomycin with the B-INA hexamer C-G-T-A-C-G (47), the aglycone ring 
of the drug intercalates between a c·c and a c·c base pair at each end 
of the helix, and the amino sugar lies flat in the bottom of the minor 
groove in a manner comparable to that of the piperazine in Hoechst, 
with even a hydrogen bond from an --OH of the aglycone ring A to 
guanine N2 and N3 atoms. Nonintercalati ve minor groove-binding drugs 
that prefer c·c-containing binding sites are rare, but chromornycin, 
mithrarnycin, and olivornycin are three related examples. Van Dyke and 
Dervan (55) have shown by footprinting studies that these drugs prefer 
at least two adjacent c·c base pairs. In the light of our Hoechst 
structure it is interesting to note that all three of these 
antibiotics contain multiple hexopyranose rings; one might expect to 
find them nested within the wider c·c regions of the minor groove, 
anchored down to guanine amines via hydrogen bonds, like the 
piperazine of Hoechst. 
One might think that a long-chain polymer of benzimidazoles would 
be an efficient and tight binder to DNA. But another problem arises 
when one follows this line of reasoning: the repeating benzimidazole 
unit, like the repeating pyrrole-amide unit of netropsin, is 25% too 
long for a match with the repetition of base pairs along the floor of 
the minor groove ( 10) • In a long polymer of benzimidazoles, the 
hydrogen-bonding N-H should quickly go out of registration with the 
base edge N3 and 02 atoms. This out-of-phasedness is clearly visible 
in Figure 5. If one considers the first atom of the Phe-Bzl, Bzl-Bz2, 
and Bz2-Pip bonds as marker atoms, then in Figure 5 the first marker 
atom (on Phe) is approximately on the same level with base pair 
-102-
A6°Tl9, the second marker atom (on Bzl) is significantly below the 
plarE of T7°Al8, and the third marker atom (on Bz2) is halfway between 
T8°Al7 and C9°Gl6. Clearly, the benzimidazole backbone of Hoechst 
33258 is a poor model for longer DNA-bonding molecules. 
When this helix repeat mismatch problem was considered with 
netropsin, a solution was found that involved replacing each -CO-NH-
amide of a poly (amide-pyrrole) chain with a shorter -00- or a -NH-
( 10). This made the repeat of the drug polymer match that of the DNA 
and still preserved the hydrogen-bonding properties necessary for 
strong DNA binding. A possible way of shortening a 
poly(benzimidazole) chain in similar fashion would be to alternate 
benzimidazole and simple imidazole rings, or to synthesize the 
repeating polymer: (-benzimidazole-benzimidazole-imidazole-) • This 
n 
in turn suggests an interesting analogue of Hoechst 33258 that would 
bind very tightly and specifically to AT regions of DNA and would 
exhibit the fluorescent behavior of Hoechst (Figure 9). Loewe and 
Urbanietz (37) observed that phenol could be replaced by another group 
as long as it remained aromatic (and, hence, presumably capable of 
delocalizing electrons into the Bzl system). Replacement of phenol by 
imidazole would accomplish this and would also furnish one more 
positive charge and one IIDre hydrogen bond donor, oriented (unlike the 
-OH of phenol) toward the floor of the groove. At the other end, 
Loewe and Urbanietz also found that piperazine could be replaced by 
another basic cation. Imidazole for piperazine would preserve both 
the charge and the hydrogen bond donor and would now be sufficiently 
narrow that it could fit down into the narrow groove of an Kr region. 
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The compoun::l in Figure 9, which might be called IBBI for 
imidazole-benzimidazole-benzimidazole-imidazole, should require a 
binding site of five successive A•T b3.se pairs and should be a 
fluorescent DNA stain of considerable affinity for DNA. 
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5. Experimental Procedures 
Synthesis of Oligonucleotide and Crystallization of Complex 
The dodecadeoxynucleotide d(C-G-C-G-A-A-T-T-C--G-C-G) was 
synthesized by the liquid-phase phosphotriester method (4, 45). The 
protected dodecamer was deblocked, and an analytical HPLC run was used 
to verify removal of the blocking groups. Two passes of the deblocked 
dodecamer through an ion-exchange DEAE Sephadex A-25 colunm were 
sufficient to produce material that was pure enough to crystallize 
readily. 
Crystals of the complex of DNA dodecamer plus Hoechst 33258 were 
grown by vapor diffusion from a solution containing 0.21 mM DNA, 0.21 
mM Hoechst 33258, 5.38 mM Mg(OAc) 2, 0.21 mM spermine acetate (pH 7.0) 
and 20% 2-methyl-2,4-pentanediol (MPD). The DNA was observed to 
precipitate out of solution upon addition of the dye, forming a 
yellowish, oily mass that slowly went back into solution during the 
course of the crystallization. Crystals grew over a period of eight 
weeks, appearing after equilibration against a reservoir containing 
35% MPD. The largest crystals were approximately 0.15 x 0.20 x 0.80 
rrnn. Precession survey photography showed them to adopt orthorhombic 
space group P212121, with cell dimensions: a= 25.04 A, b = 40.33 A, 
c = 65.85 A. 
Data Collection and Structure Analysis 
Three-dimensional x-ray diffraction data from the DNA/drug 
complex crystals were collected on a Syntex Pl-Bar diffractometer 
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using omega scan geometry, with graphite monochrometered Cu-Ka 
radiation. Data were collected to a resolution of 2.2 A, with 
approximately 45% of the 3487 unique reflections being observed above 
the two-sigma level. 
The structure of the DNA/drug complex was solved by molecular 
replacement, using the final coordinates of the native 
d(C-G-C-G-A-A-T-T-C-G-C-G) as a starting model (8). The residual 
error or crystallographic R factor between the observed and calculated 
reflections was 46.6% (zero-sigma, 8.~2.2 A resolution) prior to 
refinement. 
These initial DNA coordinates then were adjusted, without any 
assumption as to the locaton or even the presence of a drug molecule, 
during four successive stages of refinement at increasing resolution, 
using the Jack-Levitt (18) restrained refinement method. The DNA was 
refined to convergence at each stage, adjusting atomic coordinates but 
holding all temperature factors uniform at 20.0. Only when coordinate 
refinement was complete at 2.2 A resolution were temperature factors 
also set free to refine to convergence. The R factor or residual 
error at this stage was 31.7%. 
At this point, solvent peaks were clearly visible in the Fourier 
or electron density map, along with a putative Hoechst 33258 molecular 
image centered within the minor groove. In order to improve the 
phasing as much as possible, and hence to produce the best possible 
image of the drug molecule for examination, 40 solvent peaks were 
added to the structure during several further rounds of combined 
positional and temperature factor refinement, during which the R 
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factor fell to 28.0%. No solvent peaks were added, however, in the 
region where the drug moleucle was thought to lie, in order not to 
confuse the interpretation of the drug image. 
This portion of the refined electron density map then was 
examined on an Evans and Sutherland Picture System II graphics 
station, using the molecular model-building program FROOO (21). The 
otherwise un=xplained electron density down the minor groove did 
indeed have the shape expected for an image of the Hoechst 33258 
T!X)lecule at 2.2 A resolution, and the framework of the drug molecule 
was built into the density. Refin=ment, now of the complete DNA/drug 
complex, continued for several more rounds of refinement and 
examination of difference maps to pick out more solvent peaks, until 
the point was reached where it was judged that the remaining peaks 
visible in the difference map fell below the noise level of the data. 
The final structure contained one DNA double-helical dodecamer, one 
Hoechst 33258 drug molecule, and 175 solvent peaks. The final 
residual error was 0.140 for two sigma data (0.191 for all data), for 
reflections between 8.0 A and 2.2 A resolution. 
As with all structures from our laboratory, both the original 
x-ray diffraction data and the final refined coordinates have been put 
in the public domain by depositing them with the Brookhaven Protein 
Data Bank. 
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Table 1. Mean Helical Pararreters and Changes Produced ~ Drug Binding 
OOA Helix Alone DNA-drug complex 
Parameter Native MPD7 Netropsin Hoechst 33258 
t = helical 35.8°(4.2°) 36.0°(4.7°) 36 • o0 (3. 5°) 35.8° (3.8°) g twist 
n = base pairs 10.0 10.0 10.0 10.0 
/turn 
hg = rise per 3.34(0.44)A 3.37(0.52)A 3.33(0.54)A 3.39(0.44)A 
base pair 
Base pair -1. 50 (7. 30) +2.0°(4.6°) -2.9°(5.9°) -2.6°(4.5°) 
inclination 
to helix axis 
Base pair -0.17(0.95)A -0.24(0.4l)A -0.46(0.94)A -0.10(1.07)A 
displacement 
from helix axis 
Propeller twist 13.0°(5.1°) 17.7°(6.4°) 15.2° (7 .1°) 18.2°(5. 7°) 
Torsion angle 
delta: 
Purines 128.4°(20.8°) 131.2°(25.0°) 123. 6° (19. 6°) 136.1°(18.7°) 
Pyrimidines 117.0°(19.8°) 107.5°(24.7°) 105.8°(20.8°) 115.5°(27 .9°) 
Notes: The Native DNA structure has the sequence 
C-G-C-G-A-A-T-T-C-G-C-G, and has a 19° sideways bend in the overall 
helix axis (5). The MPD7 structure has 5-bromocytosine in place of 
cytosine at the 9th position and has an unbent helix axis (9). 
Netropsin was cocrystallized with the bromocytosine derivative, whose 
helix axis remained straight, whereas Hoechst 33258 was cocrystallized 
with the native DNA sequence, and the helix retained the sideways bend 
that is visible in Figure 2. In addition, the binding of each drug 
caused the helix axis to bend backward at the binding site by 7° or 
8°. For more precise definitions of helix pararreters, see Reference 9 
and the Appendix to Reference 22. 
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Figure Captions 
Figure 1. (a) Hoechst 33258 and (b) netropsin. Note the 
similarity between the two DNA-binding drugs: both are crescent-
shaped JIDlecules with flat aromatic rings and consequently would fit 
well into the minor groove of DNA. Both have hydrogen bond-forming 
N-H groups along their concave edge and an overall positive charge 
(Subscripts on nitrogens are identifying labels, not chemical 
symbols). 
Figure 2. Hydration and drug binding within the minor groove of 
the B-DNA dodecamer of sequence: C-G-C-G-A-A-T-T-C-{;-C--G. View is 
directly into the minor groove, with base pair Cl"G24 at top and 
G12"C13 at bottom. (a) CT~ alone, with the oxygen atoms of the string 
of water molecules or spine of hydration down the minor groove shown 
as crossed spheres. (b) Complex of DNA with Hoechst 33258, with the 
drug molecule in the lower half of the minor groove, and the 
undisplaced spine of hydration in the upper half. 
Figure 3. Schematics of (a) the spine of hydration, and (b) 
Hoechst 33258 with the residual spine, within the minor groove of 
C-G-C-G-A-A-T-T-C-G-C--G. Distances are from water oxygens or drug 
nitrogens, to adenine N3 or thymine 02 of DNA base pairs. Distances 
less than 4 A are dashed, and distances greater than 4 A are dotted. 
The C12 3' -OH group at the top of each diagram is from a neighooring 
DNA molecule. 
Figure 4. Stereo views depicting the alternate position of the 
piperazine ring in the DNA-Hoechst complex. (a) Piperazine buried 
-115-
within the minor groove. (b) Piperazine extended out, away from the 
double helix. Transitions between these two states must involve a 
180° rotation about the bond connecting the two benzimidazoles, and 
hence must take place when the drug is not bound to DNA. 
Figure 5. Least-squares superposition of the DNA-Hoechst complex 
(dark bonds) on the structure of the DNA alone (open bonds). Minor 
groove opens toward right. Six key phosphorus atoms are numbered: 9 
- 10 - 11 and 18 - 19 - 20, in the region of maximum widening of minor 
groove upon binding of Hoechst nolecule. For an equivalent drawing 
looking into the minor groove, see Figure 4b of Reference 24. 
Figure 6. Width of the minor groove opening, defined as shortest 
phosphorus-phosphorus distances, less 5.8 A representing two phosphate 
group radii. Phosphate numbering at bottom corresponds to that of 
Figure 5. The widening of the groove produced by Hoechst binding at 
Pl0-Pl9 and Pll-Pl8 occurs in the vicinity of the second benzimidazole 
and piperazine rings and is easily seen in Figure 5. 
Figure 7. Base plane normal vector plot, showing the bend in 
helix axis produced by the binding of Hoechst 33258. To understand 
this plot, imagine that the DNA dodecamer helix sits with its axis 
normal to the plane of the page, and with its minor groove (toward you 
in Figure 2) facing downward, along the positive y_ axis. The viewing 
direction of Figure 5 then is in from the left in this plot. 
Pip-Bz2-Bzl-Phe indicate locations of the four components of Hoechst 
as they wind around the helix axis. The ~and y_ axes are components 
of the changes in direction cosines of the normal vectors to base 
pairs 1 through 12, changes that result from the binding of Hoechst. 
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The observation that the normal vector points for base pairs 1 through 
6 cluster around one position marked by +, and that those for base 
pairs 7 through 12 cluster around a different position +, means that 
the helix axis is bent backward at its center. The distance between 
the two points +, roughly 0.12, indicates a bending of sin-1(0.12) = 
7°. The bending is in a direction away from Bz2, the second 
benzimidazole. For normal vector plots of other variants of the helix 
C-G-C-G-A-A-T-T-C-G-C-G, see References 6 and 26. 
Figure 8. Surrnnary schematics of the minor groove in free B-DNA 
of sequence: C-G-C-G-A-A-T-T-C-G-C-G, and in its complexes with two 
drug rrolecules. Sugar-phosphate oockbones are the curved sides of a 
ladder, with rungs for base pairs. Pyrimidine 02 and purine N3 (N2 
for guanines ) are circled on the rungs. Letters W indicate water 
oxygens. Dotted lines mark hydrogen bonds, although some of these are 
quite long by conventional standards. (a) Spine of hydration in the 
drug-free B-DNA helix. (b) Complex with netropsin, in which amide N-H 
groups replace the first shell waters of the spine. (c) Complex with 
Hoechst 33258, with a residual continuation of the spine of hydration 
beycnd the drug-binding site. 
Figure 9. Synthetic analogue of Hoechst 33258 that should show 
very strong DNA binding and AT-specificity, while retaining the 
fluorescent properties of Hoechst. The rightmost imidazole retains 
the aromatic character of phenol, but provides another positive charge 
and another potential hydrogen-bonding group. The leftmost imidazole 
retains the H-bonding character and positive charge of N-methyl 
piperazine, but is narrow enough to slip into an AT region of the 
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minor groove. 
Plate I. Computer graphics depiction of space-filling models of 
Hoechst 33258 bound to C-G-C-G-A-A-T-T-C-G-C-G. Colored dots define 
the van der Waals nonbonded surfaces. Stick bonds delineate the 
skeleton within. In most cases only a relatively narrow slab of 
structure is shown, in order to focus on one feature and keep the 
drawing comprehensible. 
A. Skeletal drawing of the DNA double helix, with space-filling 
dot representation of the Hoechst molecule within the minor groove. 
Red atom at upper end of Hoechst is the oxygen of the phenol -OH. 
Blue bands along the drug are the exposed benzimidazole nitrogens. 
B. Oblique cross section through the Hoechst-DNA complex, in the 
plane of the Hoechst molecule. The Hoechst phenol and two 
benzimidazoles are in light violet; the piperazine ring is shown in 
orange in its in-groove position, and in blue in its out-of-groove 
position. The DNA oose pairs beneath the drug are shown in oblique 
cross section. The upper edge of the DNA image follows the floor of 
the minor groove; the cavity at the bottom defines a cross section 
across the major groove, with phosphate groups pendant to either side. 
C. Cross section of the minor groove, through the phenol ring. 
The phenol ring has a purple skeleton with white dots outlining the 
van der Waals nonbonded contact surface. The DNA has a white skeleton 
with blue surf ace dots. The minor groove opens up and slightly to the 
right. Its opening is flanked by phosphate groups, with five-membered 
sugar rings below and base pairs in oblique cross section beneath. 
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Note that the phenol ring does not lie parallel to the walls of the 
groove, and is not fitted snugly into the bottom of the groove. 
D. Cross section of the minor groove, through the first 
benzimidazole ring (purple, with white surface-defining dots). The 
benzimidazole ring sits snugly within a narrow groove that is barely 
wide enough to acconnnodate it. 
E. Cross section of the minor groove, through the piperazine 
ring. The best mean plane through the p..ickered piperazine ring 
(purple) would make an angle of roughly 60° with a plane bisecting the 
minor groove. The piperazine can be accorrnnodated in this twisted 
orientation only because G"C regions of the minor groove are 
intrinsically wider in B-DNA than are A"T regions. Phosphates and 
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Plate IB -- DNA/Hoechst cross section with piperazine in two positions 
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Plate IC -- Cross section through phenol 
Plate ID -- Cross section through benzimidazole Bzl 
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(Not used in paper) -- Cross section throuP.h benzimidazole Bz2 
Plate IE -- cross section through piperazine buried inside groove 
